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SUMMARY
Nasal polyposis is thought to be a multifactorial disease of the nasal mucosa,
which is characterised clinically by the presence of oedematous masses in the
nasal and paranasal cavities. The disease is well-known to recur despite recent
advances in medical and surgical management. The precise mechanisms
underlying the pathogenesis of nasal polyposis are not clearly understood.
In this thesis, a literature review of recent theories of pathogenesis,
histopathology and current management of nasal polyposis is presented,
together with our findings of an immunohistochemical study of polypoidal
epithelium, in relation to its proliferation index and expression of cell cycle
markers.
Twenty-five specimens of nasal polyp mucosa and 10 specimens of normal, non-
polypoidal inferior turbinate mucosa, were investigated using technique of
immunohistochemistry. The exact protocols used in our experiments are
presented. The immunostaining of Ki-67, p21, p27, p53 and p63 within nasal
polyp mucosa and inferior turbinate mucosa were obtained. Quantification of
results was performed by 2 independent observers. Comparison of means
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between the 2 groups was performed using 2-sample t-test. The
immunohistochemical and numerical results are presented. Multiple regression
of the various immunolabelling indexes (p21, p27, p53 and p63) vs. proliferation
(Ki67) index was analysed.
We detected a statistically significant higher proliferation index in nasal polyp
mucosa. In addition, the expression of cell cycle proteins p21, p27 and p63 were
significantly decreased as compared to that of non-polypoidal mucosa. We failed
to detect any significant difference in p53 expression in nasal polyps, in contrast
to previous authors in this field. More importantly, using multiple regression, we
confirmed that the assessment of p21 and p27 immunolabelling indexes together,
is a useful predictor of Ki67 activity (increased proliferation) in nasal polyps but
not in non-polypoidal mucosa.
A discussion of our results, in the light of recent findings of the roles of the above
cell cycle markers, is presented. It is likely that with down regulation of p21 and
p27, dysregulation of epithelial proliferation is present in the diseased nasal
polyp mucosa. Perhaps, p21 and p27 may be used as plausible predictors of
biological behaviour of nasal polyps. The downregulation of p63 suggests a
dysregulation in the differentiation pattern of nasal polyps as compared to non-
polypoidal mucosa.
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INTRODUCTION
1.1 Nasal Polyposis – Clinical Background
1.1.1 Introduction
Nasal polyposis is thought to be a multifactorial disease of the nasal mucosa,
which is characterised clinically by the presence of oedematous masses in the
nasal and paranasal cavities1. The condition of nasal polyposis, though
extensively researched, is still not fully understood. It is found in a wide number
of diseases and has varied histological components determined by the basic
disease state. Hence, it may represent a common pathological end point in a
number of disease processes1.
The precise mechanisms underlying the pathogenesis of nasal polyposis are not
clearly understood. This is compounded by the lack of widely accepted
classification, which includes clinical history and histology, to differentiate
between various forms of nasal polyposis. Recurrent infections, rupture of the
epithelium and production of granulation tissue, inhaled or food allergens, T cell
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disturbances, and aerodynamic factors have all been implicated in the
pathogenesis of nasal polyps1.
1.1.2 Epidemiology
The prevalence of nasal polyps in the general population remains unclear. Few
epidemiological studies have been performed and their results are complicated
by the use of different diagnostic methods. However, the reported prevalence
seems to vary between 0.2% and 4.3% of the population.1-3 In a study conducted
in Denmark over a 6-year period by Larsen and Tos, they diagnosed 252 new
nasal polyposis patients (174 males and 78 females) to study its incidence in
background population of 223 449 inhabitants. Larsen and Tos estimated an
incidence of 0.627 per thousand per year in Denmark.4
Klossek et al reported an overall prevalence of 2.11% in France.5 In their study,
10033 subjects were screened for presence of nasal polyps by use of a validated
questionnaire/ algorithm. There is general agreement amongst authors that the
incidence rises with age and that there is a male predominance.4-5 Interestingly, a
far higher prevalence of nasal polyps is reported when autopsy specimens are
examined, with polyps present in 26-42%. 6-7  It is likely that smaller polyps may
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not present themselves clinically during life. Polyps generally remain
asymptomatic, until they progress to such a size as to obstruct the ostia of the
paranasal sinuses, resulting in symptoms of nasal obstruction and sinusitis.
However, it has not been proven that development of nasal polyps is part of the
physiological process of aging.
There are certain conditions that have a recognized association with nasal
polyps. The reported prevalence of nasal polyps in asthmatic patients varies
between 6.7% 8and 13% 9 while the prevalence of asthma in patients with nasal
polyps has been reported as high as 45%10. In 1968, Samter described the clinical
triad of asthma, aspirin sensitivity and nasal polyposis.11 Aspirin intolerance is
present in 5% to 10%12 of asthmatic patients and nasal polyposis in these patients
is far higher than the general population. The prevalence of nasal polyposis is
also higher than the aspirin tolerant asthmatic population. The reported
incidence of nasal polyps in this group of patients (Samter’s triad) varies from
36% to 95%. 13
Nasal polyposis also frequently develops in patients with other respiratory
conditions, such as chronic rhinosinusitis, cystic fibrosis, and primary ciliary
dyskinesia, in which the airway mucosal disease is widespread. The association
of nasal polyposis in cystic fibrosis is well documented. Hadfield et al. studied
211 adults with cystic fibrosis and found nasal polyps in 37%.14
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1.1.3 Clinical presentation and diagnosis
There is a wide variety of clinical presentations in patients with nasal polyposis.
Patients with nasal polyposis may present with symptoms of nasal obstruction,
loss of sense of smell (anosmia), postnasal drip, headache, and even sleep
disorders. Morbidity from nasal polyposis is related directly to the size and
location of the polyps. Obstruction of the sinus ostia frequently occurs, leading to
acute or chronic sinus conditions1,5. With continued growth and expansion,
polyps may cause bony destruction because they exert pressure on the bony
confines of the nasal cavities. In addition, polyps may cause destruction of the
nasal bones or other facial bones15.
Nasal obstruction due to polyposis can also lead to hyposmia or anosmia.5 Nasal
polyps are not known to be premalignant. However, they may be confused with
papillomas, including inverting papillomas, which are known to be precursors of
malignant lesions. In addition, polyps can sometimes arise from inflammation
caused by malignant or premalignant nasal lesions. These polyps can obstruct
visualization of the more sinister lesions and may result in delays in diagnosis. 15
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Patients with massive nasal polyposis typically present with increasing nasal
congestion, hyposmia to anosmia, changes in sense of taste, and persistent
postnasal discharge.
Headaches and facial pain/ discomfort may be accompanying symptoms, and
usually localise to the periorbital and maxillary regions. Fahy and Jones
reviewed a cohort of 973 patients with symptoms of rhinosinusitis and/ or facial
pain over a mean of 2 years 2 months. 16 Of this group of patients, 220 patients
had nasal polyps. One hundred and ninety patients had polyps without any
purulent secretions and of these, only 5 (2.6%) had pain attributable to their
paranasal sinus disease. Thirty patients (13.6%) had nasal polyposis and purulent
secretions, and within this subgroup, 24 (79%) had pain as well. The authors
conclude that in assessing patients with nasal polyps without purulent
secretions, one should be cautious in attributing any symptoms of facial pain or
pressure as being due to the paranasal sinuses. It is more probable that it is
coincidental and the result of a neurological cause. 16
In a large epidemiological study by Klossek et. al, they reported a mean duration
of nasal symptoms in nasal polyp patients as 22.4 + 15.7 years. 5 Amongst the
nasal polyp patients in this study (n=212), rhinorrhea was reported by 39.9%,
nasal obstruction by 30.8%, and anosmia by 28.9%. Only 6.9% reported facial
discomfort while 24.6% complained of general discomfort. 5 Whether a single or
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multiple polyps are present, the patient may suffer from acute, recurrent or
chronic rhinosinusitis if the polyps obstruct the sinus ostia. 5
Intranasal examination often reveals a fleshy, translucent mass or masses in the
nasal cavity, usually originating in the superior nasal vault. Polyps can be
observed originating in the ethmoid region, from the maxillary sinus ostium
(Antral choanal polyps), or rarely, the septum. Obstructing polyps may make
thorough intranasal examination difficult to attain. Mucopurulent discharge may
occasionally emanate from the ethmoid region or the superior nasal vault
suggesting an underlying rhinosinusitis. Septal deformities may further impede
the clinical examination. Nasal endoscopy in an office setting is helpful in the
diagnosis and evaluation of nasal polyps.
A thorough allergy evaluation should be considered in patients with a history of
environmental allergens or a strong family history of allergies. Children who
present with nasal polyps should be evaluated for cystic fibrosis with either a
sweat chloride test or haematological genetic testing.
With regards to imaging studies, a coronal sinus computed tomographic (CT)
scan is the radiological investigation of choice. Coronal CT of the paranasal
sinuses is ideal for delineating the underlying pathology, the extent of the
disease, and possible bony destruction. Non-enhanced CT, with 2- to 3- mm
sections, helps to delineate the location and origin of the visible polyps, evaluate
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the underlying condition of all of the sinuses, and assess the anatomy of the
paranasal sinuses in the event of surgical intervention (Figure 1).
On CT, the findings suggestive of polyposis include enlargement of sinus ostia,
rounded masses within the nasal cavity, expanded sinuses or portions of the
nasal cavity, thinning of the bony trabeculae, and less commonly, erosive bone
changes at the anterior skull base. Because the aggressive skull base erosion
might suggest a malignancy, it would be useful if there were specific findings on
MRI or CT to distinguish polyposis from cancer. Unfortunately, this is not
always possible.17 While the signal intensity of most sinonasal polyps on T2 MRI
scans is bright, this overlaps with some of the neoplasms seen in paranasal
sinuses, including sarcoma, adenoid cystic carcinomas, and minor salivary gland
neoplasms. 17
In a typical CT scan of a patient with moderate nasal polyposis (Figure 1),the
underlying bony features are clearly demonstrated with marked soft tissue
opacities within the nasal cavity. The origin of the disease is hard to define by
CT. However, it involves mainly the middle meatus, ethmoid sinuses and
maxillary sinuses (Figure 1). The inferior meatus remains clear of disease (Figure
1).
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Figure 1. CT scan of a patient with massive nasal polyposis.
The underlying bony features are clearly demonstrated. There is marked soft
tissue opacities within the nasal cavity. The origin of the disease is hard to define
by CT. However, it involves mainly the middle meatus, ethmoid sinuses and
maxillary sinuses (white arrows). The inferior meatus remains clear of disease
(marked as X).
1.1.4 Current Management and Outcomes – Medical therapy
The current management of nasal polyps consists of both medical and surgical
approaches. Ideally, treatment of nasal polyps should be based on causative
factors. Unfortunately, most cases of nasal polyps have an unclear etiology. Even
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of allergies reduces or eliminates polyps. As the underlying etiology in most
cases is inflammatory, medical management is aimed at non-specific treatment of
this inflammatory disorder.
Corticosteroids have a proven therapeutic effect on the symptoms of nasal
polyposis and may reduce inflammation18. The overall success rate for treatment
of nasal polyps with systemic steroids only was reported as 72%18. This often
dramatic effect of systemic corticosteroids has been termed “medical
polypectomy”. Systemic steroid treatment is used for short-term improvement
due to the risk of adverse effects. Hence, the use of topical steroid maintenance is
usually required due to the tendency of recurrence19.
Topical nasal steroids are delivered via drops or sprays. It has been proposed
that using drops delivers more of the drug to the middle meatus. There is good
evidence in the form of randomized controlled trials to support the use of topical
nasal steroids. Topical steroids have been shown to reduce recurrences of polyps
post-operatively and to reduce the need for repeated surgery20. Topical
corticosteroids can be used as long-term therapy either alone in mild cases or
combined with systemic corticosteroids in severe cases. The overall success rate
for the treatment of nasal polyps with topical steroids only, was reported
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between 60.9% and 80%21-22. This efficacy is maintained throughout the course of
treatment. After the cessation of treatment, the recurrence of symptoms is slow in
patients with mild polyposis and fast in patients more severely affected.
Intranasal corticosteroid sprays have a limited effect in reversing the reduced
sense of smell in a patient with nasal polyposis. In some instances, nasal sprays
may not deliver the desired dosages of drug to the site of polyp formation19.
Studies have been undertaken to evaluate the efficacy of combined (topical and
systemic) corticosteroid treatment for nasal polyps. Tuncer et al., in a prospective
study, treated patients with oral steroids for 16 days, followed by 2-month course
of topical nasal steroids23. The authors concluded that 76% of the patients
demonstrated clear involution of nasal polyps, while 12% of the patients
achieved a polyp-free cavity23. However, a significant 12% of the patients did not
respond to the treatment prescribed21. The outcome of treatment was assessed by
documentation of polyp size23.
Most of the current data regarding antibiotic therapy is based on the efficacy of
macrolides. The effectiveness of this group of antibiotics seems to be related to
their anti-inflammatory properties rather than their antimicrobial
characteristics24. Macrolides are thought to reduce fibroblast activity in vitro25.
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Most of the clinical studies of successful macrolide therapy in nasal polyposis
have originated from Japan, but these are mostly uncontrolled studies. Ichimura
et al. have noted that roxithromycin, 150 mg/ day for 8 weeks, resulted in
diminution of polyps in 52% of the patients26. However these patients had
smaller polyps to begin with, which are more likely to diminish in size26. Some
authors have advocated the use of macrolides in patients in whom corticosteroid
therapy has failed27. However, the precise role of macrolides in the treatment
algorithm has not been clearly defined.
Antifungal therapy in the management of nasal polyposis and the role of fungi in
the development of polyps remain a controversial topic.  Some believe, because
of the high prevalence of fungi noted in some studies28, that polyps may occur
secondary to chronic inflammation against fungal allergens. The prevalence of
fungal infection remains unclear, because fungal exposure differs among regions.
A survey of otolaryngologic practices throughout the United States was
conducted by Ferguson et. al. 29 It confirmed a variation of the frequency of
occurrence of allergic fungal rhinosinusitis (AFRS). The highest incidence
occurred in Memphis, Tennessee at 23%, with 3 other southern practices
reporting a frequency of al least 10%. In the northern locations, the frequency
ranged from 0% to 4%. No correlation with mould counts was demonstrated. 29
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A study using Amphoterin B nasal irrigations in general polyp patients noted
that 39% of the patients experienced endoscopic disappearance of polyps after 4
weeks of irrigation. However, there was no controlled group in this study,
making the results difficult to interpret. 30
Leukotriene modifiers, zileuton, zafirlukast and montelukast, play an important
role in the management of asthma, but limited data exist to prove their value in
nasal polyposis. Parnes and Chuma reported the benefit of zileuton and
zafirlukast among the general polyp patients, with clinical improvement seen in
72%31. Although early results seem promising, controlled and randomized
studies are required before antileukotrienes become widely used.
Intranasal capsaicin, the pungent agent in hot pepper, has been used in general
polyp patients with some degree of success in ameliorating symptoms. It appears
to act by blocking neurogenic inflammation in the nose after topical application,
resulting in the depletion of neurokinins32. This treatment has been used before
and after sinus surgery, with improvement in nasal symptoms.
Antihistamines provide symptomatic relief of allergic symptoms in patients with
nasal polyposis. However, polyp regression is not seen in these patients.
Antihistamines are not currently indicated in the primary management of polyp
patients unless there is an underlying allergic diathesis32.
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Intranasal lysine-acetylsalicylic acid (LAS) appears to have an antiproliferative
effect on fibroblasts from nasal polyps in vitro34. A controlled study revealed that
postoperative treatment with LAS in both aspirin-tolerant and aspirin-sensitive
patients diminished recurrence rates of polyps. Because both groups benefited
equally, LAS seems to act as an anti-inflammatory agent rather than through
desensitization34.
Intranasal frusemide has been shown to minimize postoperative relapse in
general nasal polyps when compared with intranasal mometasone35. Limited
data is currently available to warrant the extensive use of intranasal capsaicin,
LAS and frusemide.
Divided views exist regarding the role of allergy management in the treatment of
polyps. Some authors have suggested a full allergy evaluation and appropriate
therapy, including immunotherapy, in affected individuals. However, other
authors pointed out the lack of convincing clinical evidence to support this view.
Allergic rhinitis is a common condition and often occurs concurrently with nasal
polyps. Such patients do benefit from allergy management33.
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1.1.5 Current Management and Outcomes – Surgical therapy
Surgical treatment is directed at removal of polyps and diseased mucosa, along
with the restoration of aeration of the mucosa and sinuses. Nasal polyposis is a
chronic mucosal disease, and surgery is used only to control the disease process
once it is refractory to medical therapy. The exact timing of surgical intervention
is debatable33. One long-term follow-up study found polyps in 85% of patients
and mucosal abnormalities in 100% of patients 20 years after initial surgery,
suggesting that surgery does not reverse the underlying mucosal abnormality36.
The scope of surgery ranges from simple avulsion using headlight, surgery with
the aid of a microscope, or endoscopic removal, with or without the use of
powered instruments. More extensive surgery may be undertaken in the form of
endoscopic surgery or open sinus surgery33.
Many surgeons continue to perform simple avulsion polypectomy with the
headlight illumination finding this to be safe and effective. Larsen and Tos
followed up a large series of 243 patients who underwent this procedure37. The
follow-up period ranged from 38-145 months. They found 70% relief of
symptoms at 56 months with 80% of patients requiring 2 polypectomies or
fewer37.
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Endoscopic surgery undoubtedly offers excellent visualization and the
opportunity for precise surgery. It is today the favoured technique of many
surgeons. The advent of the Messerklinger technique has revolutionised the
operative approach of the patient with nasal polyps, and forms the basis of
functional endoscopic sinus surgery38. Functional endoscopic sinus surgery
(FESS) is based on the clinical experience that most inflammatory diseases of the
larger sinuses are rhinogenic i.e. disease spreads from the nose to the paranasal
sinuses38.
Although the clinically dominant symptoms may be due to disease in the frontal
or maxillary sinuses, in most of the cases, the underlying cause is not to be found
in the sinuses themselves, but in the lateral nasal wall. The normally very narrow
clefts of the anterior ethmoid hold the key position for the normal function and
the pathophysiology of the larger paranasal sinuses. These can be seen as
“prechambers” of the dependent frontal and maxillary sinuses, providing
ventilation and drainage for the latter. Anatomical abnormalities and mucosal
diseases (e.g. nasal polyposis) can stenose these prechambers even more and thus
predispose these spaces to recurring infections38.
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The development of a surgical concept aiming at the diseased areas in the
ethmoidal prechambers instead of the secondarily involved larger sinuses was a
logical consequence. When this technique replaced more radical open sinus
procedures in 1970, it was evident that even massive mucosal pathologies in the
dependent frontal and maxillary sinuses could heal without surgery after the
ethmoidal key areas had been cleared with limited surgery38.
Various authors have reported on the success rates of disease control after
functional endoscopic sinus surgery. Watelet et al. studied the outcome of FESS
in patients with chronic rhinosinusitis and nasal polyposis for a 6-month period.
They reported that previous sinus surgery and nasal polyposis showed
significantly worse objective outcome at 6 months post operatively39.
Dursun et al. reported a significantly poorer outcome if preoperative factors of
allergy and previous polypectomy were present40. Dufour et al. studied a cohort
of 65 patients who underwent FESS in a single institution. They reported massive
recurrences occurring in 3 patients and an anteriorly localized recurrence in 19
patients (31.7%). Bilateral normoplastic mucosa was observed in only 6 patients
(10%) at the end of the study, as local oedema was frequently associated in even
asymptomatic patients41.
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Wynn and Har-El reviewed 118 patients, in whom extensive bilateral nasal
polypectomy was performed, retrospectively42. They found 60% of patients
developing recurrences over a median period of 40 months. History of previous
surgery, allergy or asthma predicted higher recurrence and revision surgery
rates42. In conclusion, the timing and extent of surgery in nasal polyposis is still
debated amongst surgeons.
1.2 Histopathology of Nasal Polyps
1.2.1 Gross pathology
Clinically, the term, nasal polyposis, comprises all types of nasal polyps, which
emerge as blue-grey protuberances in the area of the ethmoid bone, middle
meatus nose, and middle turbinate. Nasal polyps virtually never arise from the
inferior turbinate or the septum; the reasons for this are unknown1.
Polyposis is more common in the upper part of the lateral nasal wall around the
middle turbinate, especially in the middle meatus and in the ethmoidal region
(Figure 1). This portion is an anatomic crossroad, and the mucous membrane in
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passing from the ethmoidal region, turbinate, and middle meatus undergoes
considerable variation in the composition of its stroma, especially its vascular
and glandular content. Larsen and Stammberger identified the mucous
membrane of the middle turbinate and middle meatus as the origin1.
The majority of nasal polyps enter the nasal cavity from the region of the middle
meatus1, although in conditions such as aspirin-sensitive asthma, they may be
widespread throughout the entire nasal cavity. It has been observed that polyps
form at points of mucosa to mucosa contact1. A proposed explanation for this is
that mucosal contact stimulation leads to the release of pro-inflammatory
cytokines from the epithelium.
However, anatomical abnormalities causing mucosal contact occur as commonly
in patients without rhinosinusitis as those with disease. In addition, the increased
use of the nasoendoscope, which frequently reveals contact areas within the
nasal cavity in the absence of polyps, would suggest that mucosal contact is not
the key to polyp formation. The reason why polyps are mostly localized to such a
small area of the upper airway remains a mystery1.
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Polyps are solitary and unilateral, or multiple and bilateral. Their appearance
depends largely on the makeup of the stroma. Generally, they are pear-shaped or
rounded and translucent43. In consistency, they are usually soft and gelatinous
and look like a mass of viscid mucus or the pulp of a skinned white grape43. They
are movable, do not bleed readily, and are insensitive to manipulation. The
polypoidal hypertrophy of the turbinates, however, is firmer, more sensitive to
manipulation, bleeds more freely, and is sessile43. The surface of the polyps may
be modified by hypertrophy of the epithelium or by ulceration. Their
translucency is influenced by the extent of interstitial oedema, vascularity, the
presence of haemorrhage, number of glands, presence of cysts, and the amount
of fibrosis43.
1.2.2 Histopathology
Nasal polyps are thought to represent an end-stage of chronic inflammation, and
most scientists and clinicians agree that the histopathology of the nasal polyp is
not simple oedema of the mucous membrane of the lateral wall of the nose.
Rather, it is likely to be a de novo inflammatory growth of the mucosa of the
lateral wall of the nose in the area of the uncinate process or bullar mucosa44.
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Microscopically, under the low power, the striking feature of polyps is the
looseness of the stromal structure. The delicate connective tissue cells and fibrils
are separated by clear fluid, more pronounced at the surface and decreasing
toward the periosteal portion of the mucosa. The blood vessels are widely
separated by this oedema, and they are further accentuated by the cellular
exudates that surround them44.
The surface epithelium is usually of the respiratory type, although in some areas
it may lose its cilia, be reduced by abrasion to one or two layers of cuboidal basal
cells. In other areas, it may undergo metaplasia to the squamous type. The
changes are dependent on pressure or friction from the surrounding walls, on
direct trauma, or occasionally on bacterial infection. Other causes of squamous
metaplasia are exposure to irritating air currents and longstanding friction44.
The presence of morphologic changes, such as secretory hyperplasia and
squamous metaplasia, frequently observed in the epithelium lining of the nasal
polyps, suggest underlying modifications of normal epithelial differentiation and
proliferation in nasal polyps45-46. Epithelium is likely to play an active role in the
pathogenesis of nasal polyps as well as inflammatory reactions of the lamina
propria. Respiratory epithelium, like any lining epithelium, is subjected to
continuous turnover requiring epithelial cell proliferation and differentiation for
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cell renewal and mucosal repair after various forms of aggression. Frank
malignancy, however, is almost never seen in epithelium of nasal polyps44.
The exudate consists predominantly of lymphocytes and plasma cells.
Polymorphonuclear leukocytes are usually absent. Eosinophils are present in
varying numbers, dependent upon the presence of a background of allergy and
its severity. The number of mucous glands varies with the site of origin of the
polyp. Those arising from the ostium of maxillary sinuses may contain few, if
any, mucous glands. The polyps arising from the ethmoid sinuses may not
contain any mucous glands. In contrast, the gland content is much greater in
polyps arising from the turbinates and maxillary sinuses, than would be
expected from the inclusion of the elements normally present in the original
mucosa. This suggests the presence of glandular hyperplasia in these polyps44.
Bone absorption and osteoporosis may accompany polypoidal changes in the
mucosa. These changes are often demonstrated within the middle turbinate44.
In summary, there are four major defects in nasal polyps that are markedly
different from normal nasal mucosa.19 The differences are: a marked increase in
number of eosinophils in the lamina propria of nasal polyps; an alteration of the
structure of glands in that they are fewer in number and markedly inspissated
and irregular; a large influx of water and albumin, causing oedema
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(extracellular), and a change in the architecture of the epithelium such that
normal respiratory epithelium is transformed into marked mucous cell
hyperplasia, basal cell hyperplasia, or squamous metaplasia. 19
The histological picture of polyps in cystic fibrosis has been found to differ from
the other polyps with inflammatory cells such as neutrophils, lymphocytes and
plasma cells being more common than eosinophils. Rowe-Jones at al. compared
polyps from patients with CF and non-CF patients and found eosinophilia in
both groups47. There were however significantly more neutrophils and plasma
cells in the CF polyps and more eosinophils in the non-CF group. It would
therefore appear that, although more neutrophils are present in CF polyps,
making a clear distinction between neutrophilic and eosinophilic polyps may be
unhelpful. Recurrent infections in patients with host defence deficiencies, such as
CF, may contribute to neutrophilia47.
1.3 The Molecular Biology of Nasal Polyps
In 1977, Tos first published a report outlining several possible pathogenetic
theories of nasal polyp formation48: adenoma and fibroma theories, necrotizing
ethmoiditis theory, glandular cyst theory, mucosal exudates theory, cystic
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dilatation of the excretory duct and vessel obstruction theory, blockade theory,
periphlebitis and perilymphangitis theory, glandular hyperplasia theory, new
gland formation theory and finally, ion transport theory48. Not all these theories
are extensively researched. Currently, there is no convincing evidence to support
any of the above theories. Here we will examine the current findings on various
aspects of the pathogenesis and aetiology of nasal polyps.
1.3.1 Genetics
Drake-Lee reported nasal polyposis in monozygotic twins49. High rates of nasal
polyposis (52.6%) and asthma (43.6%) have been reported in the family history of
patients presenting with nasal polyps11. An association between HLA-A1/ B8 has
been described with severe polyposis and asthma48 and between HLA-A74 and
nasal polyposis51. In a case-controlled study, Molnar- Gabor at al. showed an
increased susceptibility for developing nasal polyposis in association with the
HLA-DR7-DQAI0201 and –DQBI0202 haplotype52.
1.3.2 Inflammation of nasal polyps
Nasal polyps appear to be the clinical manifestation of an inflammatory process
characterized by stromal oedema and a variable cellular infiltrate. Although
many aspects of this process have been documented, the initiating cause remains
elusive. Indeed it is unclear whether this is the same in all cases. A number of
NASAL POLYPOSIS: MSC THESIS BY DR ANG HUI CHI, ANNETTE
35
inflammatory mediators, growth factors and adhesion molecules have been
identified within nasal polyps53.
Bernstein proposed the 4 stages of nasal polyp formation53:
Phase 1: Mucosal irritation
There is increasing evidence to suggest the airway epithelium, which has
traditionally been regarded as a physical barrier preventing the entry of inhaled
noxious particles into the submucosa, may play an important role in its capacity
as a “metabolically active” physical-chemical barrier51. Upon irritation by
noxious stimuli, it may be capable of expressing and generating increased
amounts of
1. inflammatory eicosanoids, which are potent cell activators and
chemoattractants
2. proinflammatory cytokines, which have profound effects on growth,
differentiation, migration, and activation of inflammatory cells
3. specific cell adhesion molecules, which play a vital role in intertissue
“trafficking” of the inflammatory cells
4. major histocompatibility complex (MHC) class II antigens, which play an
important role in antigen presentation to and subsequent activation of T
cells
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More recent studies of exposure of airway epithelial cells to non-allergic stimuli
have suggested the increased synthesis of inflammatory cytokines as a
consequence. Cultured human bronchial epithelial cells exposed to nitric oxide
and Haemophilus influenzae have demonstrated that these agents significantly
increase the synthesis of granulocyte-macrophage colony-stimulating factor
(GM-CSF), interleukin (IL) - 8, and tumour necrosis factor (TNF)-α in vitro. 54
Stimulation of epithelial cells by various agents may lead to generation of
different cytokine profiles and subsequent activation of specific inflammatory
cells. The very early development of nasal polyps in the lateral nasal wall may be
the result of stimulation of the epithelium by aerodynamic changes; allowing
irritants to metabolically or physically alter or injure the surface epithelium53.
Phase II: Tumour necrosis factor-α (TNF−α) and interleukin-1β (IL−1β)
These two cytokines are often expressed in the epithelium of nasal mucosa once
an irritant stimulus is encountered. They lead to the upregulation of the
expression of endothelial adhesion molecules involved in inflammatory
reactions, essentially endothelial adhesion molecule (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) 53. These chemoattractants play a dual role by
triggering integrin activation and directing leukocyte migration. Several
chemokines, such as eotaxin and RANTES (regulated upon activation, normal T-
NASAL POLYPOSIS: MSC THESIS BY DR ANG HUI CHI, ANNETTE
37
cell expressed and secreted), have been shown to attract and activate eosinophils
in vitro and to recruit eosinophils into inflammatory lesions with little effect on
neutrophils53. Furthermore, RANTES induces selective transendothelial
migration of eosinophils in vitro. The selectivity of different cytokines for
different leukocyte subsets, aid in the understanding of preferential recruitment
of particular cell types in various inflammatory reactions53. Eosinophils are
clearly the predominant cell type in nasal polyps, consisting up to 80% of the
inflammatory cells53.
Phase III: Eosinophils
The potential to cause damage to the epithelium is related to the inflammatory
mediators of eosinophils, particularly major basic protein (MBP). Eosinophil
cationic protein has been shown to stimulate airway mucous secretion, whereas
eosinophilic MBP inhibits airway mucous secretion. Jacoby et al. published the
first study on the role of MBP and its effect on chloride secretion, which
demonstrated that MBP increased net chloride secretion53. Bernstein’s laboratory
further demonstrated that MBP significantly increases the sodium flux into the
interior of the epithelial cell53. Although there was a large movement of chloride
both in and out of the cell, there appeared to be no significant net flux of
chloride. Finally, the short-circuit current appeared to be remarkably increased
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with MBP in contrast with the control. In his speculations, this finding is
interesting in the therapeutic implications of the effects of amiloride. Amiloride
significantly decreased the sodium absorption and decreased the short-circuit
current. He postulated a possible use of amiloride as a topical agent to decrease
sodium absorption into the cell and thus possibly decrease cellular and
subcellular oedema53.
Phase IV: Dysregulation of fluid and electrolyte transport. Sodium channels and
cystic fibrosis transmembrane regulator (CFTR) alteration.
The large quantity of extracellular fluid present in polyps would suggest
dysregulation of fluid and electrolyte transport. This may be explained by the
presence of inflammatory mediators as many of these, in particular, histamine,
are well known to increase vascular permeability. Vascular endothelial growth
factor is a potent mediator of both angiogenesis and vascular permeability. This
protein is expressed in nasal polyps to a higher degree than surrounding nasal
mucosa.53 The cystic fibrosis transmembrane regulator gene (CFTR) is an active
chloride pump that plays a critical role in fluid homeostasis and a genetically
determined abnormality of this protein is known to occur in cystic fibrosis. The
CFTR is also abnormally located in the polyps of non-CF patients. However, the
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significance of this knowledge is unclear at present and may simply be a
consequence of chronic inflammation53.
1.3.3 Epithelial alterations in nasal polyps
Together with an inflammatory infiltrate, extracellular oedema and presence of
inflammatory mediators, morphologic changes such as secretory hyperplasia and
squamous metaplasia are frequently observed in the epithelium lining nasal
polyps. These findings are suggestive of modifications of normal epithelial
differentiation and proliferation in nasal polyps56. Studies on the proliferative
activity of respiratory epithelium in nasal polyps have been published. Coste et
al demonstrated significantly higher proliferating cell nuclear antigen (PCNA)
indexes in nasal polyps than normal mucosal epithelium (suprabasal area and
full height of mucosal epithelium) with immunohistochemical methods56. In
addition, they demonstrated significantly higher percentage of S-phase cells in
nasal polyps compared with normal mucosal epithelium, by flow cytometry. In a
related study, they related this increased epithelial proliferative index with an
increased in platelet-derived growth factor (PDGF) 57.
They demonstrated increased activated macrophages in the leucocytic infiltrate is
nasal polyp epithelium and lamina propria when compared to normal mucosa55,
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as indicated by an increase in the expression of CD-68, a marker of activated
macrophages. In addition, PDGF expression also appeared to be intense in
hyperplastic and metaplastic areas of nasal polyp epithelium, associated an
increase in activated macrophages55. As activated macrophages are a well-known
source if PDGF in various tissues, especially the airways, the authors suggested
that activated macrophages in nasal polyps are a major source of PDGF which
contributes to the epithelial proliferation. 55
Hassid at al. studied the proliferative activity in nasal polyps in relation to the
four subgroups of polyps – namely, single polyp, massive polyps, ASA polyps
(present in patients with Samter’s triad) and CF polyps. The authors determined
that the CF polyps exhibited the highest proliferative activity of all the clinically
identified nasal polyp groups58.
Nakagawa et al similarly reported higher epithelial PCNA indexes in nasal
polyps, associated with higher fibroblastic PCNA indexes. They further
suggested the importance of fibroblasts in the pathogenesis of nasal polyps59.
Bruno et al. further correlated the cellular proliferation index of nasal polyps to
the relapse of nasal polyps. Using methods of flow cytometry, the percentage of
cells in S phase of the cell cycle is studied. They divided their test population into
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3 groups of low, medium and high percentages (of cells in S phase of cell cycle).
The patients from whom the polyps have been obtained are followed up for at
least 3 years after the conduct of surgery. They reported a clinical relapse
(defined as a recurrence at least 6 months after surgery) rate of 15%, 70% and
100% in each of the low, medium and high percentage of S-phase cell groups of
patients. It is likely that those polyps with a high proliferative index at the onset
have a higher tendency for recurrence60.
Similarly, Welkoborsky et al. used methods of routine histology, quantitative
DNA measurement and immunohistochemical identification of proliferation
markers (i.e. MIB-1, PCNA) to study 50 specimens of nasal polyps. Quantitative
DNA analysis demonstrated diploid stemlines and lack of aneuploid cells in
most cases. Immunohistochemical detection of proliferation markers showed low
proliferation rates in all cases. In 27 polyps, no MIB-1 expression was detected,
and in 7 polyps no PCNA expression was detected. Nasal polyps of 10 patients
with recurrent disease displayed higher scores for proliferation markers, and in 5
cases of these, aneuploid cells (1.5-11.7% of cells) were detected. The authors
concluded that in recurrent disease, some increase in proliferation activity and
some changes in parameters of DNA analysis occurred, indicating more
aggressive behaviour of recurrent polyps than in single polyp cases61.
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It is highly likely that factors, such as genetic predisposition, environmental
antigens and anatomical aberrations in the nasal cavity, come together to present
a favourable ground for development of nasal polyps. The body’s unique
response to such antigens and insults result in an influx of inflammatory
mediators which subsequently contribute to downstream events of epithelial
damage, dysregulated ion transport and epithelial proliferation, eventually result
in the genesis of nasal polyps.
Current management paradigms serve to ameliorate symptoms and delay
recurrences of this disease. However, the key to complete eradication and
prevention of nasal polyps remains very much the Holy Grail in the quest of
practising physicians and researchers.
1.4 Control of the mammalian cell cycle
1.4.1 The mammalian cell cycle
Dividing normal cells execute an ordered set of steps called the cell cycle that, by
convention is divided into four phases62: G1, a phase during which the cell
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prepares to synthesize DNA; S, a period of DNA synthesis; G2, a period in which
preparations are made for cell division and finally, M, the mitotic phase itself.
Cells in the body that are not actively dividing may be either terminally
differentiated, thus unable to re-enter the cell cycle, or in a state of temporary
arrest called G0. In addition, the cell cycle may be arrested at G1 or G2
‘checkpoints’.62 Arrest at these checkpoints occur when damage in the DNA
content is detected.
The molecular machinery of the cell cycle, and the factors that control the various
stages of progression from G1 to M, have been substantially researched. At the
heart of the cell cycle regulatory apparatus, is a family of enzymes called the
cyclin-dependent kinases (Cdks). They regulate a number of downstream target
molecules by phosphorylation. The downstream target molecules of Cdks carry
out the steps that lead ultimately to DNA replication and mitosis.  62
Passage through the restriction point (G1) and entry into S phase is controlled by
Cdks that are sequentially regulated by cyclins D, E and A. In general, Cdk
activity requires cyclin binding, which depends on both positive and negative
regulatory phosphorylation. The Cdks are inhibited by two families of Cdk
inhibitory proteins, named for their apparent molecular weights62.
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Cyclins and cyclin-dependent kinases (cdks) are essential for cell-cycle control in
eukaryotes. Cyclins (regulatory subunits) bind to cdks (catalytic subunits) to
form active cyclin-cdk complexes. Cdk subunits, by themselves, are inactive and
binding to a cyclin is required for their activity. The concentrations of the
regulatory subunits of these kinases or cyclins, increase and decrease in phase
with the cell cycle. Cyclins A, B1, D, and E undergo periodic synthesis and
degradation, thereby providing a mechanism to regulate cdk activity throughout
the cell cycle. Cdk activity is further regulated by activating or inhibitory
phosphorylation, and by small proteins (p14, p16, p21, and p27), called inhibitors
of cdk activity. The inhibitors then bind to cyclins, Cdks, or cyclin-cdk
complexes. Active cyclin-cdk complexes drive cells through particular cell cycle
phases, called checkpoints, by phosphorylating the unique sets of protein
substrates that are essential to achieve transition to the next phase. 62
The members of the INK4 family Cdk inhibitory proteins are p16INK4a, p15INK4b,
p18INK4c and p19INK4d. Each has four ankyrin repeats and form complexes with
Cdk and/ or Cdk6 and the D-type cyclins. The members of the second group of
Cdk inhibitors, the Cip/ Kip family, include p21Cip/ waf1, p27Kip1, and p57Kip2. Each
has a homologous amino terminal domain containing contiguous cyclin- and
Cdk-binding regions. These Cdk inhibitory protein molecules have several
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hallmarks of tumour suppressors and are perfectly positioned to regulate critical
decisions in cell proliferation62.
The expression and interaction of these three types of molecules (Cdks, cyclins
and Cdk inhibitors) account for timing of events in the cell cycle. For example,
constitutive overexpression of cyclin E results in shortened G1 interval.
Depletion of Cdk 2 activity by dominant negative mutant forms or by anti-Cdk2
antibodies causes G1/S arrest62.
Orderly cellular proliferation and differentiation in the eukaryotic cell cycle is
coordinated by cyclin-dependent protein kinases (Cdks) and cyclin subunits
specific for the different phases of the cycle (See Figure 2). These complexes
phosphorylate target substrates, including the retinoblastoma susceptibility gene
product (pRb) and related proteins62. Dyskinetic cellular proliferations are
accompanied by loss of regulation of cell cycle checkpoints, frequently through
aberrant expression of Cdks and cyclins, as well as loss or mutation of their
negative regulators62. The underlying modifications of normal epithelial
proliferation and differentiation in nasal polyps have not been extensively
researched in current medical literature.
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Figure 2a. Diagrammatic representation of the cell cycle. The complexity of cell cycle
regulation is illustrated. The ultimate result is that of highly co-ordinated activities of
reproduction at an appropriate timing in every normal cell. (Reproduced with permission
from BD Biosciences)
Cyclins and cyclin-dependent kinases (cdks) are essential for cell-cycle control in
eukaryotes. Cyclins (regulatory subunits) bind to cdks (catalytic subunits) to form active
cyclin-cdk complexes. Cdk subunits, by themselves, are inactive and binding to a cyclin
is required for their activity. Cyclins A, B1, D, and E undergo periodic synthesis and
degradation, thereby providing a mechanism to regulate cdk activity throughout the cell
cycle. Cdk activity is further regulated by activating or inhibitory phosphorylation, and by
small proteins (p14, p16, p21, and p27), called inhibitors of cdk activity, that bind to
cyclins, Cdks, or cyclin cdk complexes. Active cyclin-cdk complexes drive cells through
particular cell cycle phases, called checkpoints, by phosphorylating the unique sets of
protein substrates that are essential to achieve transition to the next phase.
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Figure 2b. Simplified representation of the eukaryotic cell cycle.
At the G1 check point, p21, p27 and p53 (amongst other regulator proteins) are
important proteins that determine the passage of the reproducing cell through this
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1.4.2 Cell Cycle regulator proteins
1.4.2.1 p21 cell cycle regulator protein
p21 (also called WAF1, CAP20, CIP1, and Sdi1) is the founding member of the
Cip/Kip family of Cdk inhibitors, which also includes p27 and p57. These three
Cdk inhibitors contain a conserved region of sequence at the NH2 terminus that
is required and sufficient for the inhibition of cyclin-cdk complexes, whereas the
COOH terminal regions are variable in length and function. They can bind and
inhibit a broad range of cyclin-cdk complexes; with a preference for those
containing Cdk261. p21 plays an essential role in growth arrest after DNA
damage, and overexpression leads to G1 and G2 arrest or S-phase arrest.63
Cell cycle protein p21 is a major negative regulator of p53-dependent apoptosis.
In response to radiation and chemotherapy, p53 protein is stabilised and
mediates apoptosis and cell cycle arrest (See Figure 3). Whereas the mechanisms
of p53-dependent apoptosis are not well understood, p53-dependent cycle arrest
is primarily mediated by the CDK inhibitor p2164. It is not entirely clear how a
cell chooses between apoptosis and p21-dependent cell cycle arrest after DNA
damage and stabilization of p53, but studies have shown that high levels of p21
expression mediate cell cycle arrest and protect from p53-dependent apoptosis63.
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The p21 promotor contains two conserved p53-binding sites, and at least one of
these is required for p53 responsiveness after DNA damage. p21 functions in the
response of most mammalian cells to DNA damage, working in concert with p53
protein64.
Figure 3 . p53-induced cell-cycle arrest in response to DNA damage.
The normally unstable p53 protein is stabilised by damaged DNA, so its concentration
increases. Acting as a transcription factor, p53 induces expression of p21 CIP, a cyclin-
kinase inhibitor that inhibits all Cdk-1, Cdk-2, Cdk-4 and Cdk-6 cyclin complexes.
Binding of p21CIP to these Cdk-cyclin complexes leads to cell cycle arrest in G1 and G2.
(Adapted from Molecular Cell Biology64)
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In addition, a variety of transcription factors that are induced by a number of
different signalling pathways activate p21 transcription by p53-independent
mechanisms, including Sp1, Sp3, Ap2, STATs, C/EBP alpha, C/ERP beta, and the
bHLH proteins BETA2 and MyoD. p21 expression may be regulated
postranscriptionally by both ubiquitin-dependent and –independent
proteasome-mediated degradation63.  In metastatic prostatic cancer cell lines, p21
gene is inactivated by promotor methylation. p21 gene expression was low or
undetectable in the metastatic prostate cancer cell lines but highly expressed in
normal prostate cells. 64 Following treatment with demethylating agent , 5-Aza-
Cdr, p21 was re-expressed in the prostate cancer cell lines. In sequence analysis
of the promotor region, several sites of methylation at the 5’ end of a CpG island
in the PC3, LNCaP and DU 145 cell lines were detected. These sites of
methylation were not present in normal prostate controls. 64  p21 expression is
induced during the irreversible growth arrest of cellular senescence and appears
to be an important regulator of senescence in human fibroblasts. Overexpression
of p21 led to induction of a panel of genes expressed in different age-related
diseases63.
In vivo, p21 has been shown to play roles in regulating renewal of keratinocytes
and haematopoietic cells63. It plays a role in the control of T-cell proliferation, and
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female p21-deficient mice have decreased viability and develop a syndrome
similar to human lupus. In the kidney, p21 appears to regulate the balance
between hyperplasia and hypoplasia, and its disruption ameliorates progression
to chronic renal failure after partial renal ablation63. p21 induction was correlated
with differentiation of muscle, and embryos lacking both p21 and p57 have
severe defects in the formation of skeletal muscle and altered lung development,
suggesting redundant functions for p21 and p57 during development.66 Aging
studies in p21-deficient mice have demonstrated a role for p21 in tumour
suppression, albeit a much weaker one than p53. Mice deficient for p21 and INK4
cyclin kinase inhibitors p18 have increased incidence and progression of
pituitary tumours, with most animals developing tumours by one year of age67.
Mice lacking p21 are found also to be more susceptible to chemically induced
skin carcinomas67. Loss of p21 was associated with earlier development of
mammary gland tumours, increased tumour multiplicity, and aggressiveness in
MMTV/v-Ha-ras mice. It was also shown to synergize with Rb and INK4a/ARF
to protect against tumour progression in mice. 63 In the mouse mammary
hyperplasia model, the progression from hyperplasia to tumour is associated
with decrease in total p21 levels. Generally, the levels of p21/ Cdk 2 are
decreased in all hyperplasia phenotypes compared with normal mammary gland
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under control conditions. Hence, p21 is important in benign hyperplasia and
progression to metaplasia. 68
1.4.2.2 p27 cell cycle regulator protein
p27 cell cycle protein is active in the G1 phase of cell division.  The p27 tumour
suppressor gene is located on chromosome 12p13. It was identified as an
inhibitor of cyclin-dependent kinase-2 (cdk-2)65. The p27 protein bears some
similarity to p21 and also inhibits several CDKs. Downregulation of p27
accompanies progression through G1 phase and is permissive for the periodic
activation of cyclin E-cdk 2 and cyclin A-cdk269.
The antimitogenic role of p27 was reinforced by the p27-knockout mouse, which
is larger than its wild-type littermate. Homozygous p27-/- mouse embryos
develop normally through birth. However, by several weeks of age, the mutant
mice are 30% larger than wild-type animals because of a general
overproliferation of cells in most organs. 70 Although p27-/- cells undergo more
cell cycles than normal, most eventually arrest in G1 and develop normally.
Thus, although p27CIP clearly contributes to the normal control of cell
proliferation, other mechanisms also restrain cell cycling, especially during
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embryonic and foetal development70. A decrease or absence of p27 protein
expression has been shown to be associated with more aggressive clinical
behaviour in a variety of human tumours, including breast, lung, colon, gastric
and ovarian carcinoma.
 p27-/- mice, in addition to multiorgan hyperplasia, also exhibited increased
susceptibility to cancer in multiple tumour models. A low level of p27 is a
marker of poor prognosis in several human adenocarcinomas.  However, no
mutations in the p27 gene have been reported to date70. In keeping with its role
as a negative regulator of cell cycle, levels of p27 are high in quiescent cells but
decreased in response to mitogens. Intracellular levels of p27 are largely
controlled by the rate of p27 degradation, which occurs through the
ubiquitination and subsequent proteasome-mediated proteolysis70. Recent
studies have shown that p27 is recognised by an F-box protein, SKp2 of the Skp1-
Cullin-F-box protein (SCF) complex, which mediates ubiquitination and
subsequent degradation of the phosphorylated p27 by the ubiquitin-proteasome
pathway. Over expression of SKp2 may result in low cellular p27. Other
mechanisms of control of p27 include failure of nuclear import and
methylation.71
Ledford et al. studied the expression of homeobox gene Cux-1 in transgenic mice
results in downregulation of p27 expression during nephrogenesis. These mice
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developed multiorgan hyperplasia and organomegaly, but not overall increase in
body size. When Cux-1 was ectopically expressed in more highly differentiated
tubules and glomeruli of the transgenic mice, there was reduced expression of
cyclin kinase inhibitor, p27. 72 Abid et al. studied the forkhead transcription
factors that inhibit the vascular smooth muscle cell proliferation and neointimal
hyperplasia. Under in vitro conditions, platelet-derived growth factor (PDGF),
tumour necrosis factor α, and insulin-like growth factor 1 stimulated
phosphorylation of FoxO in human coronary artery smooth muscle cells via
MEK ½ and/ or phosphatidylinositol 3-kinase-dependent signalling pathways.
This resulted in downregulation of the target gene of FoxO, p27, resulting in
enhanced survival and progression through the cell cycle. 73
In mouse mammary hyperplasia model, p27 concentration level and cellular
localization in the mammary epithelial cells determine its potential for breast
tumour development. Low p27 levels are associated with high tumour grade,
high cyclin E/ cdk2 activities, reduced disease-free survival and loss of estrogen
receptors (ER), suggesting that low p27 is a powerful and independent
prognostic marker of poor clinical outcome in breast cancer. 68 In addition to its
role in carcinogenesis, p27 protein is increasingly recognised as an important
regulator in benign hyperplasia and early cancers.
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1.4.2.3 p53 cell cycle regulator protein
p53, a transcription factor expressed in all cells, is the most frequently genetically
altered tumour suppressor in human cancers. The p53 gene is located on the
short arm of chromosome 1767. The corresponding p53 protein is able to inhibit
DNA synthesis and cellular entry into the S phase of the cell cycle. 74 It has a
short half-life (20 to 30 minutes) and is therefore expressed at low levels in
normal cells. In tumours where p53 itself remains intact, p53 function can be
inactivated by genetic alterations of other genes in the p53 pathway, including
the deletion of the alternative reading frame gene. 74 p53’s transcriptional
program protects cells against the destructive effects of DNA-damaging agents,
including γ irradiation or chemotherapeutic drugs or oncogenic stresses from
hyperproliferative signals induced by activated proto-oncogenes, such as Myc or
Ras. 74
p53 suppresses tumour growth by halting cell proliferation, a process called
premature senescence, or by triggering a cell suicide program, also known as
apoptosis74. However, the p53-regulated genes which control each of these two
outcomes have not been completely mapped.
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Apoptosis, or programmed cell death, is an active process activated in response
to DNA damage. Mutations in the apoptotic pathway, including p53, lead to
tumourigenesis and resistance to chemotherapeutic agents in cell lines and in
vivo74. Senescence was originally defined as a mechanism that limits the lifespan
of fibroblasts by a finite number of divisions. Replicative senescence, the
“Hayflick limit”, is linked to the progressive shortening of telomeres leading to
the physiological process of aging74. Therefore, apoptosis and senescence both
constitute failsafe mechanisms through which cells are forced to irreversibly exit
the cell cycle, and by doing so, prevent cells from unscheduled growth and
cancer.
p53 has been implicated in the regulation and control of replicative  and
premature senescence. Mouse embryo fibroblasts (MEFs) from p53-deficient and
Arf null mice are immortal and fail to enter the premature senescence75. Mice
lacking either of these two tumour suppressors develop a variety of tumours
refractory to therapy75. Similarly, human tumours lacking p53 function are
resistant to chemotherapy. Small molecules that reactivate mutant p53 by
restoring its DNA binding activity and transcriptional activity were reported to
provide anti-tumour activity in vivo75.
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1.4.2.4 p63 cell cycle regulator protein
The p63 gene, a homologue of the tumour-suppressor p53, is highly expressed in
the basal or progenitor layers of many epithelial tissues. p63 is expressed in the
ectodermal surfaces of the limb buds, branchial arches and epidermal
appendages, which are all sites of reciprocal signalling that, direct the
morphogenetic patterning of the underlying mesoderm76.
Yang et al. reported that mice homozygous for a disrupted p63 gene have major
defects in their limb, craniofacial and epithelial development76.  The limb
truncations were due to a failure to maintain the apical ectodermal ridge, a
stratified epithelium, essential for limb development. The embryonic epidermis
of p63+ mice undergoes an unusual process of non-regenerative differentiation,
culminating in a striking absence of all squamous epithelia and their derivatives,
including mammary, lacrimal and salivary glands76. The authors concluded that
p63 is critical for maintaining the progenitor-cell populations that are necessary
to sustain epithelial development and morphogenesis76.
p63 shows remarkable structural similarity to p53 and to the related p73 gene.
Unlike p53, however, several messenger RNAs are transcribed from 2 different
promoters of p63 gene, yielding both transactivating (TA-p63) and non-
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transactivating  (N-p63) isotypes. p63 is strongly expressed in the basal, or
progenitor, cells of several epithelial structures present in the epidermis, cervix,
urogenital tract, prostate and breast76.
The importance of p63 function in epithelial differentiation was revealed by the
remarkable absence of skin and related appendages in late embryonic and
newborn p63- deficient mice in the experiments of Yang et al.  They found that
there was absence of a stratified epithelium in p63-/- mice which lacked the
characteristic structure of basal, suprabasal and cornified layers and associated
hair follicles. 76
In addition, the tissues derived from the same stem cells that give rise to the
epidermis, including mammary, sebaceous, lacrimal and salivary glands, were
also absent in the p63-/-  mice.  Instead of an epidermis, p63-/- late-stage embryos
and newborns retain isolated patches of disorganized epithelial cells along the
exposed dermis. Further histological studies revealed the absence of a normally-
stratified squamous epithelium on the tongue, and its replacement by one or two
layers of cuboidal epithelium. Similar abnormalities of the epithelial layer were
observed in the oesophagus, stomach and cervix. 76
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The authors’ findings highlighted a strong correlation between p63 expression in
epithelial progenitor cells and its absolute requirement in the normal
development of stratified squamous epithelium. p63 is highly expressed in basal
cells but is rapidly degraded upon their differentiation. It is likely that p63
preserves the self-renewal capacity of progenitor cells that undergo asymmetric
division to yield simultaneous regenerative and differentiated cell fates. 76
p63 exists as multiple isotypes of two subclasses, TA (transactivating) and ρN. 77
ρNp63 isotypes are thought to antagonize transcription by TAp63 and p53, and
are highly expressed in squamous cell cancers.  Using mouse keratinocytes as a
biological model of squamous epithelium, it has been shown that multiple p63
isotypes, ρN- and TA-containing, are expressed and differentially modulated
during in vitro murine keratinocyte differentiation.77 ρNp63α declines with Ca2+ –
induced differentiation, while a smaller ρN-form, ρNp63s, persists, suggesting
unique functions of the two isoforms. King et al. investigated the impact of
dysregulated p63 expression that is observed in cancers and the biological
contribution of the different domains of the p63 isotypes, ρNp63α, ρNp63p40 and
TAp63α; using techniques of microarray, RT-PCR and Western blot analysis in
mouse keratinocytes. 77   
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Specific p63 isotypes are expressed during distinct stages of embryonic
epidermal development and roles attributed to these isotypes are beginning to be
elucidated. Embryonic expression of TA p63 coincides with the onset of the
epidermal stratification program and ectopic expression of TAp63α can initiate
stratification of simple epithelium. 77  Within the developed epidermis, ρNp63α
has been postulated to maintain keratinocytes in a proliferative state. Consistent
with these findings, chemically induced tumours of the skin are shown to
express high levels of ρNp63. The authors also demonstrated that multiple p63
isotypes are expressed in normal primary neonatal keratinocytes and are
individually modulated with in vitro differentiation. 77
Unlike ρNp63α, the authors found that overexpression of ρNp63p40 was
compatible with keratinocyte differentiation. Overall, the maintenance of the
balance of p63 isotypes is critical for keratinocytes growth regulation. The TA
and ρNp63 isotypes have been shown to possess overlapping as well as unique
functions and are capable of regulating each other.77
1.4.2.5 Role of cell cycle proteins in nasal polyposis
The most commonly mutated tumour-suppressor gene associated with human
cancer, p53. The p53 protein functions in the checkpoint control that arrests
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human cells with damaged DNA in G1, and it contributes to arrest in G2. Cells
with functional p53 arrest in G1 or G2 when exposed to γ-irradiation, whereas
cells lacking functional p53 do not arrest in G164. Although p53 is a transcription
factor, under normal circumstances, it is extremely unstable; thus it generally
does not accumulate to high enough levels to bind to p53-control elements and
activate transcription. Damaged DNA stabilises p53 protein through yet
unknown mechanisms, leading to an increase in its concentration64.
One of the genes whose transcription is stimulated by p53 encodes p21. p21
binds to and inhibits all mammalian cyclin-cdk complexes. As a result, cells are
arrested in G1 and G2 until DNA damage is repaired and p53 and subsequently
p21 levels fall62. With this close relationship in mind, we included the study of
p21, together with p53, in our study. p27, being one of the three known
mammalian cyclins, was included.
As p63 protein plays an important role in the regulation of proliferation and
differentiation in the progenitor cells of the basal layer of the ectodermal
epithelium. Nasal polyps essentially arise from the sinonasal epithelium, whose
origins lie in the ectodermal layer. With this in mind, we too included p63
protein in our study.
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While the roles of p21, p27, p53 and p63 are widely studied in embryology and
carcinogenesis, there is very little data on the role of these cell cycle regulator
proteins in the pathogenesis of nasal polyposis. In addition to the role of these
proteins in carcinogenesis, they increasingly recognised as important regulators
in benign hyperplasia and early cancers. A comprehensive study of these
proteins in regulation of development of a benign process like nasal polyposis is
certainly timely.
1.5 Methodology: A review of immunohistochemistry
1.5.1 Development of detection technique in histopathology
The conceptual and technical basis for immunocytochemistry were first laid in
the 1940s by Albert Coons in his attempts to localize antigens and antibody
responses related to pathogenic microorganisms in tissues of infected and
immunized animals. For detection of the disease-associated antigen, he invented
the direct immunofluorescence method utilizing fluorescein-labelled primary
antibody directed against the antigen.78
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As for tracing plasma cells involved in specific antibody response to the
pathogen, he developed the antigen sandwich method. This used unlabelled
antigen as the primary probe and fluorescein-labelled antibody to the antigen as
the secondary detection antibody reagent. In both these studies he found frozen
tissue sections prepared from unfixed tissue to be an optimum substrate. 78
The orientation of these pioneering studies by Albert Coons (His original aim
was to trace streptococcal antigens in diseased tissues taken patients dying of
rheumatic fever) towards microbial immune responses unfortunately prevented
an earlier introduction of immunocytochemistry to histopathological practice. 78
The technique of immunocytochemistry has since rapidly developed to become a
powerful tool in molecular diagnostics and histopathological practice today.
1.5.2 The Avidin-biotin complex (ABC) procedure
The avidin-biotin method was introduced by Hsu et al in the early 1980s. It
represents a considerable improvement in efficiency compared to the prototype
avidin-biotin bridge system originally proposed by Avrameas et al in the early
1970s. 78
The ABC is a three-step procedure consisting of an unlabelled primary antibody
(added in the first step), an affinity-purified, biotin-labelled anti-immunoglobulin
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reagent specific to the primary antibody immunoglobulin species (added in the
second step) and a preformed avidin-biotin-labelled peroxidase complex with a
free valency for biotin (added in the third step). The three layers form a complex
(Figure 2) at the tissue-binding sites of the primary antibody molecules79.
Figure 4. Avidin-Biotin Complex
In the ABC technology, the avidin- or streptavidin-biotin enzyme complex reacts
with the biotinylated secondary antibody71
1.5.3 Antigen Retrieval (AR) methods in Immunohistochemistry
The antigen-antibody (Ag-Ab) reaction in immunohistochemistry (IHC) usually
takes place between two protein macromolecules: the antigen, which may also be
a glycoprotein, a lipoprotein, or just a protein, and the antibody, which is a
glycoprotein. The antigen is located in section of formaldehyde-fixed, paraffin-
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embedded tissue. The conformation of the antigen protein has suffered the effect
of the formaldehyde fixative and may have been modified in its constitution or
its conformation. 80
According to Mason and O’Leary, the original secondary structure of the
proteins, in formaldehyde-fixed tissue, has been effectively locked in by the
process of fixation80. Routine formaldehyde fixation and procedure for paraffin
embedding is known to decrease the intensity of the final reaction in the IHC
procedure.  Biochemical studies of the chemical reaction between protein and
formalin by Fraenkal-Conrat et al. in 1940s indicated that hydrolysis of
crosslinkages between formalin and protein is limited by certain amino acid side
chains, such as imidazol and indol, but that these crosslinkages can be reversed
by high-temperature heating (120oC) or strong alkaline treatment73. This
observation formed the basis for the development of antigen retrieval techniques
in 1991.
A simple method of either heating the routinely fixed paraffin-embedded tissue
sections in water or immersing the routinely formalin-fixed, acid decalcified,
celloidin-embedded tissue sections in a NaOH-methanol solution yielded
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dramatic retrieval results. The AR technique has been used increasingly and has
demonstrated its value in many studies for over 200 antibodies.81
The worldwide use of AR-IHC has, however, raised some questions concerning
the methodology of heating, the factors that influence the AR-IHC, the variety of
AR solutions used for heating the tissue sections, limitations and possible false
positive staining and the mechanism of AR. 81
The methodology of AR is influenced primarily by the following factors73:
1. The effect of heating
Shi et al. demonstrated that an optimal result of AR-IHC is correlated with the
product of heating temperature (T) X time of AR heating temperature (t). “T X t”
means the heating condition. The lower the temperature of heating used for AR,
the longer the time required to reach the same intensity of AR-IHC compared
with that obtained by higher-temperature heating. 81
2. The effect of pH
Although some antigens yield satisfactory results by AR treatment with the use
of distilled water, other antigens require heating in buffers of specific pH to
obtain the strongest intensity of staining. A few antigens yielded satisfactory
results only when buffers within a limited pH range was used (e.g. MAb to
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thrombospondin, when used on archival paraffin sections, required AR-IHC of
low pH 1-2 AR solution).
Essentially, Shi73 classified pH effects on staining patterns into three groups:
stable type, which changed slightly with pH; V-form type, which gave best
results only at extremes of pH; ascending type, which stained better with
increasing pH. On the basis of their findings, Shi et al. recommends the use of AR
solution at higher pH value for general application, giving results that are
marginally superior to the pH value of 6 in widespread use today. Although the
low-pH AR solutions may yield strongest intensity for some antibodies such as
ER, PR, Rb, thrombospondin and MIB1, weak false-positive nuclear staining may
also be found in focal areas, giving rise to background staining.81
3. The effect of molarity
For citrate and other buffers in widespread use for AR, molarity is not a major
issue.81
4. The effect of metal ions
Many authors debate on the role of metal ions in the outcome in antigen
retrieval. Metal salts are not a necessary component of the AR buffer. 81
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5. The AR solution
Although the chemical components of the AR solution may play a role as a
possible co-factor in the heating procedure, there has been no single chemical
identified that is essential and best for AR. To determine the ideal AR solution,
Shi el at. recommend the use of a “test battery” of solutions. It may be possible to
obtain equally good results with several AR solutions. 81
1.5.4 Chromogen choice for immunoperoxidase staining
The most favoured chromogen for the immunoperoxidase method is
diaminobenzidine (DAB). The obligate substrate of the peroxidase enzyme,
hydrogen peroxide H2O2, oxidatively polymerises diaminobenzidine to a brown
polymeric compound, which has the following characteristics, making it the first
choice chromogen for immunoperoxidase staining reactions78.
The DAB polymer is a highly tenacious substance, which sticks virtually
instantaneously and irreversibly to the tissue at the precise site of its generation.
The DAB polymer is also very resistant to alkalis, acids and various dehydrants
such as alcohol and xylene, and is therefore a virtually permanently stable
product, which does not diffuse or fade in its intensity even after many years of
storage. 78
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The colour or shade of the DAB deposit varies from smooth yellow or dark
brown, which contrasts well with the blue of the haematoxylin nuclear
counterstain widely used in histopathological practice. The DAB polymer has a
high affinity for heavy metal salts such as osmium tetroxide, gold chloride, cobalt
chloride, etc, allowing its colour intensity and quality to be improved for light as
well as electron microscope viewing. 78
1.6 Objectives of Study
We formulate the hypothesis that in the presence of abnormal polypoidal
mucosa, there is likely to be aberrations of underlying cell cycle mechanics in the
epithelium. Though there may not be clear-cut mutations as present in malignant
cells, we hypothesise that the cell cycle dynamics may be altered but not to the
extent of unregulated growth as seen in cancers. The epithelial growth and
differentiation is dysregulated but certain inhibitory factors are perhaps still
present.
We undertake to test this hypothesis by immunohistochemical staining of nasal
polyp tissue and inferior turbinate mucosa of the patients, of expression of cell
cycle regulator proteins (p21, p27, p53, p63 and Ki-67 antigen) in the epithelial
cells. These proteins are important in G1 phase of the cell cycle.
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An altered expression of any protein will indicate cell cycle aberrations. With
reference to Section 1.4, we have highlighted the important roles played by p21,
p27, p53 and p63 in the control of the mammalian cell cycle, their roles in
tumourigenesis and our rationale for selection of these cell cycle markers for
investigation. (See Figure 2b)
Studies have been done to demonstrate the effect of a single factor (whether a
chemokine, cytokine or cell cycle regulator protein) in the pathogenesis of nasal
polyp/ chronic rhinosinusitis disease56-61. However, in our study model, we
propose to investigate the expression of several of the important cell cycle
proteins and their relative distribution in diseased nasal mucosa and grossly
normal inferior turbinate mucosa of the patients. We also propose to determine
whether any (or all) of these cell cycle proteins exhibit a correlation with the
proliferation of the epithelium, in nasal polyps.
We hope that this will lead us to a fuller understanding of the complex
interactions between many factors in the pathogenesis of this disease and
perhaps, the proposal of use of cell cycle proteins as markers of biological
behaviour in nasal polyps.
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MATERIALS AND METHODS
2.1 Sample population and Controls
Twenty-eight cases of nasal polyposis were retrieved from the pathology
archives of National University Hospital. The archived tissues were obtained
from patients who had undergone functional endoscopic sinus surgery (FESS) at
the Department of Otolaryngology, Head & Neck Surgery, National University
Hospital, from January 2003 to December 2003. The specimens obtained were
anonymous archival samples.
Ten samples of normal inferior turbinate mucosa were obtained from patients
undergoing surgery for nasal septal deviation, obstructive sleep apnoea or other
unrelated conditions. These patients did not report symptoms of allergic rhinitis
or rhinosinusitis. The inferior turbinate mucosa was grossly normal, with no
evidence of infection or inflammation. The inferior turbinate mucosa obtained
was immediately fixed in 10% neutral buffered formalin for 24 hours and
processed in an automated tissue processor. Paraffin embedding was
subsequently performed using Leica tissue embedding centre. Please refer to
Appendix II for detailed protocols.
These samples were used as normal controls in this study.
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2.2 Cell cycle markers
The primary antibodies against the panel of cell cycle markers under
investigation were obtained from the manufacturers as shown in Table 1.
Table 1. Sources of primary antibodies used.
Primary antibody Clone Manufacturer
Ki-67 MIB-1 Dako, Denmark
p21Ab-11 CP74 LabVision, US
p27Ab-1 DCS72.F6 LabVision, US
p53 DO-7 Dako, Denmark
p63 A4A Dako, Denmark
The Ki-67 antigen is a nuclear protein, which is defined by its reactivity with
monoclonal antibody from the Ki-67 clone. The Ki-67 antigen is preferentially
expressed during all active phases of the cell cycle (G1, S, G2 and M phases), but
it is absent in resting cells (Go phase). During interphase, the antigen can be
exclusively detected within the nucleus, whereas in mitosis, most of the protein
is relocated to the surface of the chromosomes. The antigen is rapidly degraded
as the cell enters the non-proliferative state and there appears to be no expression
of Ki-67 during DNA repair processes82. Monoclonal mouse anti-human Ki-67
antigen antibody (Clone MIB-1) is raised against human recombinant peptide
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corresponding to a 1002 bp Ki-67 cDNA fragment. The antibody has been shown
to cross-react with the Ki-67 equivalent protein in humans and various other
mammals including cow, dog, horse, sheep and swine. Sections of tonsils with
reactive germinal centres were used as positive controls for Ki67 antigen
immunolabelling. Sections of studied tissue with diluent solution in substitution
of primary antibodies were used as negative controls83.
Monoclonal p21 Ab-11 (Clone CP74) is raised in mice against a full length human
recombinant p21 protein. Its species reactivity includes both human and rat.
Sections of colon carcinoma were used as positive controls. Sections of studied
tissue with diluent solution in substitution of primary antibodies were used as
negative controls. p21 is a tumour suppressor protein. Expression of p21 is
induced by wild type, but not mutant p53 suppressor protein. The p21 protein
binds to cyclin-cdk complexes and inhibits their kinase activity, thereby stopping
cell cycle progression84.
Monoclonal p27 Ab-1 (Clone DCS-72.F6) is raised in mice against mouse
recombinant p27 protein. Its species reactivity includes human, mouse, rat and
dog. Sections of colon carcinoma were used as positive controls. Sections of
studied tissue with diluent solution in substitution of primary antibodies were
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used as negative controls. p27, a candidate tumour suppressor gene, functions as
a negative regulator of G1 progression and has been proposed to function as a
possible mediator of TGF-β induced G1 arrest85.
Monoclonal mouse anti-human p53 antibody (Clone DO-7) is raised against
recombinant human wild-type p53 protein. p53 is a nuclear phosphoprotein with
a molecular weight of 53 kDa. Wild-type p53 protein is present in a wide variety
of normal cells, but the protein has a very short half-life and thus is present in
only minute amounts, generally below the detection level of
immunocytochemical methods. Somatic mutation of the p53 gene is a very
common event in the development of human neoplasia and because mutant p53
proteins often are much more stable than wild-type p53 protein, the mutant p53
proteins accumulates to a high level. Sections of colon carcinoma were used as
positive controls in the process of immunohistochemistry. Sections of studied
tissue with diluent solution in substitution of primary antibodies were used as
negative controls86.
The sections of colon carcinoma used as controls for p21, p27 and p53 have been
previously demonstrated over-expression of the said cell cycle regulator marker.
Three different blocks of archival colon carcinoma (i.e. arising from 3 different
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patient sources) were used as positive controls for the immunostaining
procedure of p21, p27 and p53 markers.
Monoclonal mouse anti-human p63 protein antibody (Clone 4A4) is raised
against glutathione-S-transferase (GST) – p63 recombinant protein which
comprises amino acids 1-205 of the N-terminal portion of Np63 protein. In
Western blotting of lysates of primary human foreskin keratinocytes, human
cervical carcinoma (ME180), baby hamster kidney cells and normal prostate
stromal cells which express different p63 isotypes (TAp63α, TAp63γ, ρNp63α
and ρNp63γ), the antibody (clone A4A) labels bands corresponding to the
different p63 isotypes. It is not specific for any particular p63 isotypes. In normal
tissues (e.g. foreskin, uterine cervix, vagina, urothelium, and prostate), the
antibody strongly labels the nuclei of proliferating basal cells of epithelial layers
in the epidermis. In abnormal tissues (e.g. prostate carcinoma, non-small cell
lung carcinoma), dysplastic cells were negative with the antibody, but a rim of
residual p63-positive basal cells could be identified.
Sections of normal prostate were used as positive controls during the process of
immunohistochemistry. Sections of studied tissue with diluent solution in
substitution of primary antibodies were used as negative controls87. In summary,
the clone of p63 antibody used identified all subclasses of the p63 protein.
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2.3 Ethics and consent
The protocol was approved by the review and ethics board of our institution,
National University Hospital. Informed consent was obtained from all patients
from whom inferior turbinate mucosa was obtained, for use of tissue for research
prior to surgery and tissue collection.
2.4 Tissue handling
Retrieved paraffin-embedded archival samples and inferior turbinate paraffin-
embedded samples were cut at 3 micrometers in thickness (Leica rotary
microtome) and mounted on poly-L-lysine coated slides.
Deparaffinization and rehydration was performed for all sections, using xylene
and graded ladder (in decreasing strengths) concentration of alcohol solutions.
Universal precautions were carefully observed for all procedures involving
human/ animal tissue or harmful chemicals.
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2.5 Immunohistochemistry protocol
For each specimen, a section was systematically stained (Haematoxylin and
eosin) for standard histomorphological analysis. The deparaffinized sections
were subjected to a standard antigen retrieval technique, using TRIS-EDTA
buffer (pH 9.0) and Micromed T/T system. Heating to 90oC at 400W was
performed for 20 minutes. The horseradish peroxidase technique was used for
immunohistochemistry.
All antibodies were diluted in diluents obtained from manufacturers of the
primary antibodies. Five different primary antibodies were used at the following
dilutions (See Table 2). The dilution and incubation period listed were
determined by repeated experiments using positive control slides, for optimal
staining conditions.
Table 2. Dilution and incubation period of primary antibodies
Primary antibody Incubation period Dilution
Ki-67 60 min at room temperature 1:100
p21Ab-11 60 min at room temperature 1:100
p27Ab-1 60 min at room temperature 1:100
p53 Overnight at 4oC 1:50
p63 Overnight at 4oC 1:100
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The same technique was applied to nasal polyp and inferior turbinate samples.
After antigen retrieval, the sections were incubated in hydrogen peroxide (0.3%)
for 30 minutes to quench endogenous peroxidase activity. They were then
incubated with blocking antibody serum (LabVision, USA) for 30 minutes.
Primary antibodies were incubated with the tissue sections for 60 minutes at
room temperature or overnight at 4oC as indicated by Table 2. When incubation
was completed, the sections were thoroughly washed with buffer solution.
Biotinylated secondary goat anti-mouse antibodies (LabVision, USA) were then
applied to the sections for 30 minutes. The sections were washed with buffer
solution.  Streptovadin peroxidase (LabVision, USA) was incubated with the
sections for 30 minutes. The sections were thoroughly washed with buffer
solution. Substrate solution with diaminobenzidine (DAB) was used as a
chromogen. It was added to the sections for 10 minutes.
All incubations were performed in a moist chamber after which the sections were
washed with TRIS-buffered saline (pH 7.6). Tissue sections were counterstained
with haematoxylin (Gill 3 haematoxylin, SciMed). The slides were dehydrated in
increasing concentrations of alcohol and cleaned in xylene. They were mounted
with cover slips with the use of a permanent mounting medium (DPX medium,
Merck).
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2.6 Quantification and Statistical Analysis
2.6.1 Quantification
Epithelial cells with clear, dark nuclear staining (brown) were counted as
positive cells. Assessment of the slides was done at 1:40X magnification. Each 100
micrometers of unbroken length of epithelium was counted for dark-staining
cells. The total number of epithelial cells was also assessed for the same length of
epithelium.
Percentage of positive cells was obtained = No of dark staining nuclei x 100%
Total no of cells
The microscopic examination was conducted by 2 independent observers. A total
of 3 randomly selected fields were assessed for each slide. The average
percentage as calculated above was taken. The raw data is presented in
Appendix III.
2.6.2 Statistical analysis – comparison of means between polypoidal 
mucosa group and non-polypoidal mucosa group
The one-sample t test is a statistical test of hypothesis to compare the unknown
mean of a single population to some fixed, known value, μ0. In practical
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applications, however, it is far more common to compare the means of two
different populations, where both means are unknown. Often, the two groups
may have received different treatment or undergone different exposures88.
The two sample t test is a variation of the one-sample t test. It is used in such a
situation. The means of each group of results were analysed using the two-
sample t test for independent samples. In using the two-sample t test, the
assumption of normal distribution within both populations from which the
random samples are drawn is made.
Secondly, the assumption of equal variance for the two populations is made.
Lastly, the two samples are assumed to be independent. However, it is essential
to note the t test is rather robust to non-normality.  Confidence intervals of 95%
are set for the rejection of null hypothesis (there is no difference in staining index
between the two populations). For an observed difference to be statistically
significant, p value must be less than or equal to 0.05.88 The SPSS package was
used in the computing of the statistics.
NASAL POLYPOSIS: MSC THESIS BY DR ANG HUI CHI, ANNETTE
81
2.6.3 Multiple regression of variables
The simple linear regression model assumes that the mean of the response
variable, y, depends on the explanatory variable, x, according to a linear equation
μy = β0 + β1x
For any fixed value of x, the response, y varies normally around this mean and
has a standard deviation, σ, that is the same for all values of x. In the multiple
regression setting, the response variable, y, depends on not one but p
explanatory variables. The mean response is a linear function of the explanatory
variables and can be expressed as: 81
μy = β0 + β1x1 + β2x2+ β3x3 + β4x4 ……+ βpxp
This is the population regression equation.  In each subpopulation, y varies
normally with a mean given by the population regression equation. The
regression model assumes that the standard deviation s of the responses is the
same in all subpopulations.
To construct the multiple linear regression model, the population regression
equation and assumptions about variation are combined. The subpopulation
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means describe the “fit” part of the statistical model while the “residual” part
represents the variation of the observations about the means. The symbol ε
represents the deviation of an individual observation from its subpopulation
mean. We assume these deviations are normally distributed with the mean 0 and
an unknown deviation σ that does not depend on the values of the x variables.
Hence the statistical model for multiple linear regression is 89
yi = β0 + β1xi1 + β2xi2+ β3xi3 + β4xi4 ……+ βpxip + ei
for i = 1,2, …., n
The mean response μy is a linear function of the explanatory variables:
μy = β0 + β1x1 + β2x2+ β3x3 + β4x4 ……+ βpxp
The deviations εi are independent and normally distributed with mean 0 and
standard deviation σ. In other words, they are an SRS from the N (0,σ)
distribution. The parameters of the model are β0, β1, β2, .., βp and σ.
Using the multiple regression model, we analysed the correlation of the various
cell cycle markers with proliferation (Ki-67) index. This statistical analysis was
performed using the Excel (Windows XP) package. 89
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RESULTS
3.1 Comparison of epithelial architecture of polypoidal mucosa and non-
polypoidal mucosa
3.1.1 Non-polypoidal mucosa demonstrated normal respiratory epithelium
A total of 25 specimens of nasal polyps were examined. The remainder 3
specimens were disregarded as a result of inadequate length of intact epithelium
for assessment. This is likely due to specimen destruction during surgery. All 10
specimens of inferior turbinate (normal non-polypoidal mucosa) were assessed.
The histological slides, prepared with hematoxylin and eosin (H & E) stain, are
presented.
Normal respiratory epithelium is present in the non-polypoidal mucosa of the
inferior turbinate specimen. It is pseudostratified and columnar.
The basal layer consists of a one-cell thick layer, orderly arranged on the basal
membrane. The cilia are clearly demonstrated with neat arrangement of goblet
cells. Submucosal glands are regular in appearance. There is no extracellular
oedema. These features are clearly demonstrated in Figure 5.
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Figure 5. Inferior turbinate from a non-allergic patient (Non-polypoidal mucosa)
1:40X
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3.1.2 Changes in epithelial architecture are present within the polypoidal
mucosa
In contrast, the epithelial architecture of polypoidal mucosa is demonstrated in
Figure 6 and Figure 7. Within the nasal polyp, the respiratory mucosa shows
areas of transitional epithelium, with irregular proliferation of epithelial cells
(Figure 6). The surface epithelium, though usually of the respiratory type, has
lost its cilia. In other areas, the epithelial layer has been reduced by abrasion to
one or two layers of cuboidal basal cells (See Figure 7, black arrow). There is a
decreased numbers or absence of goblet cells in the epithelial layer of nasal
polyps (Figure 6 & 7) . In some areas of the nasal polyp mucosa, there is evidence
of squamous metaplasia (Figure 7).
The submucosal glands appeared irregular and poorly developed. Blood vessels
are sparse and immature. The blood vessels are widely dilated especially those
near the surface where they have lost the support of the denser normal stroma
(Figure 7).
There is an intense cellular infiltrate seen in the submucosal layers of the tissue
(Figures 6 and 7). The exudate consists predominantly of lymphocytes and
plasma cells.
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Figure 6. Nasal polyp (H & E stain)
This slide demonstrates the presence of an inflammatory cell infiltrate. The respiratory
mucosa shows areas of transitional epithelium, with irregular proliferation of epithelial
cells. There is presence of proliferation of irregular submucosal glands. Blood vessels
are sparse and immature.
1:40X
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Figure 7. Nasal polyp (H & E stain)
This slide demonstrates the presence of squamous metaplasia in the respiratory
epithelium, and an intense cellular infiltrate. Black arrow shows area where the cuboidal
cells are reduced to one-two cells thick, likely the result of abrasion or contact with other
mucosal surface.
1:40X
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3.2 Expression of Ki-67 antigen as a measure of proliferation index
3.2.1 Detection of higher proliferation index in epithelium of polypoidal
mucosa as compared with that of non-polypoidal mucosa
Ki-67 immunolabelling is evident as darkly staining (brown) nuclei within the
epithelial layer of cells. In nasal polyps (refer to Figure 8), the Ki-67 labelled cells
are present throughout the thickness of the epithelium, not merely restricted to
the basal layer. In areas with evidence of squamous metaplasia there is increased
Ki-67 immunolabelling.
In the non-polypoidal mucosa, there is preservation of the normal respiratory
epithelium, with the presence of goblet cells and cilia. This is evidence of normal,
regulated cellular differentiation. Ki-67 immunolabelling in non-polypoidal
epithelium is restricted to the occasional cell in the basal layer of the epithelial
cells.
The mean staining index for Ki-67 for nasal polyp mucosa is 14.15 (+ 7.51) while
that of normal mucosa is 4.16 (+ 1.16) (See Table 3). There is a significantly higher
proliferative index in the epithelium of nasal polyps (p < 0.001).
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Figure 8. Nasal polyp – Ki-67 immunolabelling
Significantly increased number of nuclei stained darkly in the epithelial layer for Ki-67
marker as compared to normal mucosa (Figure 9). In addition the labelled cells are
present throughout the thickness of the epithelial layer.
1:40X
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Figure 9. Non-polypoidal mucosa – Ki67 immunolabelling
Sparse number of epithelial nuclei stained positively for Ki-67 marker (arrow). The
labelled cells are mostly located at or near the basal layer.
1:40X
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3.3 Comparison of expression of cell cycle markers
3.3.1 Differential expression of p21 cell cycle protein in epithelium of
polypoidal and non-polypoidal mucosa
There is very sparse p21 immunolabelling within the epithelial layer of the nasal
polyp mucosa. In many areas, there is almost no nuclear labelling of p21 (Figure
10). This is more evident in areas of squamous metaplasia (Figure 10).
Within the epithelial layer of the non-polypoidal mucosa, there is intense
staining of the suprabasal layer of cells (p21 immunolabelling), as evident in
Figure 11. The epithelium is well-differentiated. The apical cells of the
epithelium, however, demonstrate very sparse p21 immunolabelling.
The mean p21 immunolabelling index in nasal polyp mucosa is 1.46 (+1.01) while
that of normal mucosa is 24.53 (+10.25) (Table 3). The difference in staining index
of p21 in nasal polyp mucosa and normal mucosa is significant (p < 0.001).
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Figure 10. Nasal polyp – p21 immunolabelling
Sparse number of nuclei stained darkly for p21. Squamous metaplasia is present.
1:40X
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Figure 11. Non-polypoidal mucosa – p21 immunolabelling
Increased amount of p21 immunolabelling seen in suprabasal cells of the epithelial layer.
The epithelium remains well-differentiated.
1:40X
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3.3.2 Differential expression of p27 cell cycle protein in epithelium of
polypoidal and non-polypoidal mucosa
Similar to p21 immunolabelling, p27 immunolabelling of nuclei of epithelial cells
within nasal polyp mucosa is very sparse (Figure 12).  The few p27-
immunolabelled cells are found scattered throughout the thickness of the
epithelial layer. There is presence of squamous metaplasia in the epithelium
(Figure 12).
The p27 immunolabelling of the epithelial cells of non-polypoidal mucosa is
noted to be intense. The p27-labelled cells are found mainly within the
suprabasal layer of the epithelium. As expected, the normal respiratory epithelial
pattern is preserved within the non-polypoidal mucosa.
The p27 immunolabelling index for p27 for nasal polyp mucosa is 5.16 (+3.78)
while that of non-polypoidal mucosa is 35.51 (+11.16). (See Table 3) The
difference in staining index of p27 in nasal polyp mucosa and normal mucosa is
significant (p < 0.001).
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Figure 12. Nasal polyp – p27 immunolabelling
Sparse number of darkly-stained nuclei within the epithelium (arrows).
1:40X
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Figure 13. Non-polypoidal mucosa – p27 immunolabelling
A fair amount of the suprabasal cells of epithelium were darkly stained (arrows). The
normal respiratory epithelium is preserved. There is presence of mild background
staining in the cytoplasm of the epithelial cells in this slide. (We detected uniformly
increased background staining within the cytoplasm of the epithelial cells in all the
specimens)
1:40X
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3.3.3 Differential expression of p53 cell cycle protein in epithelium of
polypoidal and non-polypoidal mucosa
In all cases obtained for p53 (both polypoidal and non-polypoidal mucosa), it
was noticed that the staining intensity was low and cell nuclei were mostly
negative.
In both nasal polyp and non-polypoidal mucosa, there is presence of few darkly
stained, p53-immunolabelled epithelial cells scattered throughout the thickness
of the epithelial layer (Figure 14 and 15).  As before, normal respiratory epithelial
pattern is preserved in the non-polypoidal mucosa, while the nasal polyp
mucosa demonstrates squamous epithelium.
The mean p53 immunolabelling index for nasal polyp is 5.97 (+5.37) while that of
non-polypoidal mucosa is 2.51 (+1.00). (See Table 3) The immunolabelling
indexes for both groups of tissues were not found to be statistically significant.
This is likely due to the high variability between the samples within both groups.
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Figure 14. Nasal polyp – p53 immunolabelling
Presence of p53 immunolabelled cells scattered throughout the epithelial layer (arrows)
1:40X
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Figure 15. Non-polypoidal mucosa – p53 immunolabelling
Presence of p53 immunolabelled cells scattered within the epithelial layer (arrows)
1:40X
NASAL POLYPOSIS: MSC THESIS BY DR ANG HUI CHI, ANNETTE
100
3.3.4 Differential expression of p63 cell cycle protein in epithelium of
polypoidal and non-polypoidal mucosa
Within the nasal polyp mucosa, there is presence of a single layer of darkly
staining, p63 immunolabelled cells along the basal membrane (Figure 16). This
layer of cells is rarely more than 2-cell thick. Squamous metaplasia is present in
the epithelium of the nasal polyp mucosa.
In contrast, within the non-polypoidal mucosa, there is a 2-cell to 4-cell thick
layer of darkly staining, p63 immunolabelled cells along the entire length of the
basal membrane (Figure 17).  This staining is consistently maintained along the
length of the basal layer of the epithelium. The epithelium is well-differentiated
into its specialised cells (goblet cells, ciliated cells). Only the well-differentiated,
mature cells are negative of p63 immunolabelling.
The mean p63 immunolabelling index for nasal polyp mucosa is 36.31 (+11.76)
while that of non-polypoidal mucosa is 59.42 (+13.28). (See Table 3) The
difference in staining index of p63 in nasal polyp mucosa and normal mucosa is
significant.
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Figure 16. Nasal polyp – p63 immunolabelling
 Darkly-stained nuclei mainly at lowest level of basal cells (arrows)
1:40X
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Figure 17. Non-polypoidal mucosa – p63 immunolabelling
Darkly-stained nuclei were apparent at 2- to 4- cell thick layer at the basal level of the
epithelium (arrows)
1:40X
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3.3.5 Summary of differential expression of proliferation and cell cycle
proteins in epithelium of polypoidal and non-polypoidal mucosa





Ki-67 14.15 + 7.51 4.16 + 1.16 0.001
p21 1.46 + 1.01 24.53 + 10.25 0.001
p27 5.16 + 3.78 35.51 + 11.16 <0.001
p53 5.97 + 5.37 2.51 + 1.00 0.07
p63 36.31 + 11.76 59.42 + 13.28 <0.0001
Table 3. Proliferation index and expression of cell cycle proteins in
epithelium of polypoidal and non-polypoidal mucosa
Using p<0.05 (confidence levels of 95%), we detected a significant difference in
staining indexes of p21, (p=0.001), p27 (p=0.001) and p63 (p=0.001). However, this
difference in staining is not evident in the case of p53 staining index in nasal
polyps as compared to non-polypoidal tissue.
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3.4 Correlation of various cell cycle markers to proliferation index using 
the multiple regression model
3.4.1 Multiple regression of 4 cell cycle markers (p21, p27, p53 and p63) 
vs. proliferation (Ki-67) index in nasal polyps
To analyse the correlation of the various cell cycle markers (p21, p27, p53 and
p63) with proliferation (Ki-67) index in nasal polyps, we performed multiple
regression on the data (See Table 4). In our multiple regression model,
proliferation (Ki-67) index was used as the dependent variable (y co-ordinate)
while the cell cycle markers were used as explanatory variables (x co-ordinates).
The F value of this multiple regression was 0.17 (p>0.05),not statistically
significant. The four cell cycle variables when considered together, did not
impact the proliferation index. In addition, it was evident that p53 cell cycle
marker variable showed the least significance (p=0.699). We next performed
multiple regression analysis with the exclusion of p53 cell cycle marker to further
evaluate the other three cell cycle markers.
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 df SS MS F
Significance
F
Regression 4 228.6104 57.1526 1.766416 0.175262
Residual 20 647.1022 32.35511
Total 24 875.7126    
 Coefficients
Standard
Error t Stat P-value Lower 95% Upper 95%
Intercept 14.00331 3.570643 3.921791 0.000845 6.555088 21.4515415
p21-N -0.5457 0.476775 -1.14457 0.265902 -1.54024 0.44883364
p27-N -0.30534 0.199539 -1.53024 0.141621 -0.72157 0.1108876
p63-N 0.056275 0.103244 0.545066 0.591735 -0.15909 0.27163684
p53-N 0.119355 0.303967 0.392657 0.698726 -0.51471 0.75341932
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3.4.2 Multiple regression of 3 cell cycle markers (p21, p27 and p63) vs. 
proliferation (Ki-67) index in nasal polyps
To further analyse the variables (cell cycle markers p21, p27, p53 and p63), the
variable showing the least significance, p53 cell cycle marker, was excluded from
the next analysis (See Table 5)











 df SS MS F
Significance
F
Regression 3 223.6219 74.54063 2.400514 0.096491
Residual 21 652.0907 31.05194
Total 24 875.7126    
 Coefficients
Standard
Error t Stat P-value Lower 95% Upper 95%
Intercept 14.32273 3.406011 4.205132 0.000398 7.239538 21.40591
p21-N -0.54584 0.467075 -1.16863 0.25565 -1.51717 0.425499
p27-N -0.30127 0.195215 -1.54329 0.137696 -0.70725 0.104698
p63-N 0.064266 0.099159 0.648112 0.523937 -0.14195 0.270477
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The F value of this multiple regression was 0.096 (p>0.05). The 3 cell cycle
variables when considered together, do impact the proliferation index. The p
value however, is reduced after the exclusion of p53 cell cycle marker in this
multiple regression. In our earlier section 3.3.5, we presented a statistically
significant difference in the p21, p27 and p63 immunolabelling indexes between
nasal polyps and non-polypoidal mucosa.
This multiple regression model of p21, p27 and p63 vs. proliferation index
further confirms that p21, p27 and p63 indeed possibly play a role in the
modulation of epithelial proliferation in nasal polyps. In the multiple regression
model presented in Table 5, p63 cell cycle marker demonstrated the largest p
value (i.e. least significant) for correlation with proliferation index. We
proceeded to exclude this variable from our next analysis.
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3.4.3 Multiple regression of 2 cell cycle markers (p21 and p27) vs. 
proliferation (Ki-67) index in nasal polyps
We performed a multiple regression on two variables (p21 and p27) vs.











 df SS MS F Significance F
Regression 2 210.5786 105.2893 3.482552 0.048531
Residual 22 665.1341 30.23337
Total 24 875.7126    
 Coefficients
Standard
Error t Stat P-value Lower 95%
Upper
95%
Intercept 16.33257 1.389941 11.75055 5.94E-11 13.45 19.21513
p21-N -0.61117 0.450014 -1.35812 0.18819 -1.54445 0.322098
p27-N -0.2496 0.175828 -1.41958 0.169745 -0.61425 0.115043
Table 6. Multiple regression of p21 and p27 vs. proliferation index in nasal
polyps
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The F value for this multiple regression model of p21 and p27 cell cycle markers
vs. proliferation index was 0.049 (p<0.05). The correlation of p21 and p27 with
proliferation index was clearly significant. A decrease in p21 and p27
immunolabelling clearly correlated with an increased proliferation index.
Interestingly, when the variables, p21 and p27, were tested individually against
proliferation index, the analyses did not return a significant F value. This finding
suggests that proliferation of epithelial cells in nasal polyps correlated with a
combined decrease in p21 and p27 expression rather than either one of them
alone. Surprisingly, the inclusion of p63 cell cycle marker weakened the
correlation with proliferation index (See Section 3.4.2). To test if the multiple
regression model we applied was appropriate for our data set, we examined
residual plots of p21 and p27 as predictors of proliferation index.











Figure 18. Plot of residuals vs. explanatory variable p21
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Figure 19.  Plot of residuals vs. explanatory variable p27
In both residual plots of p21 and p27 as predictors of proliferation (Ki-67) index,
the plots appear to show more or less random noise around the center value of 0.
Thus our assumptions of the multiple regression model can be applied to the
data sets of p21, p27 and proliferation index.
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3.4.4 Multiple regression of 2 cell cycle markers (p21 and p27) vs. 
proliferation (Ki-67) index in non-polypoidal mucosa
To further confirm that this relationship only occurs in nasal polyps, this
multiple regression model was performed in non-polypoidal mucosa, using the
same variables (p21 and p27) and proliferation index of the non-polypoidal
mucosa (See Table 7).











 df SS MS F
Significance
F
Regression 2 10.38596 5.192978 3.205753 0.102724
Residual 7 11.33925 1.619893
Total 9 21.72521    
 Coefficients
Standard
Error t Stat P-value Lower 95% Upper 95%
Intercept -1.22532 2.251373 -0.54426 0.603162 -6.54897 4.098325
p21-T 0.075617 0.032094 2.356121 0.050629 -0.00027 0.151507
p27-T 0.099507 0.046815 2.125513 0.07114 -0.01119 0.210207
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The F value for this model was 0.10 (p>0.05), clearly not statistically significant.
The negative correlation of p21 and p27 with proliferation index in nasal polyps
was not demonstrated in non-polypoidal mucosa.
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DISCUSSION
4.1 Epithelial proliferation is increased in nasal polyps
Polyps of the nasal cavity and the paranasal sinuses can be considered benign
neoplasms that are frequently associated with chronic inflammation1. Allergic
diathesis, production of distinct neurosubstances (i.e. cytokines), infiltration with
eosinophils and T cells, and environmental insults in the paranasal sinuses are
regarded as parameters supporting polyp development1.
Although it is clearly established that inflammation is a constant feature of nasal
polyps, the relations between inflammation and nasal polyp growth have not
been clearly elucidated. The presence of morphologic changes in the respiratory
epithelium of the nasal polyps (e.g. squamous metaplasia, secretory hyperplasia)
and a recurrence rate of up to 55% suggest dysregulated proliferation of the
epithelial cells61.
From the results reported above, we concur with other authors in this field that
the proliferation index of epithelial cells in nasal polyps is increased as compared
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with normal mucosa. We found a significantly raised proliferation index of 14%
in nasal polyp mucosa, as compared with 4.51% in non-polypoidal inferior
turbinate mucosa. Similar results have previously been reported by several
authors56-61.
Coste et al demonstrated increased cell proliferation in the respiratory
epithelium of nasal polyps, with the use of flow cytometry (to determine cell
DNA content and percentage of S-phase cells) and immunohistochemistry58
(proliferating cell nuclear antigen expression). All cell populations studied were
diploid, and percentage of S-phase cells was significantly higher in nasal polyps
than in mucosa of inferior turbinate. Proliferating cell nuclear antigen (PCNA)
indexes were significantly higher in nasal polyps than in the suprabasal area and
full height of the normal mucosal epithelium. 56
These findings are consistent with our findings, where the Ki-67
immunolabelling of epithelial cells in polypoidal mucosa is present in all layers
of the epithelium, while in non-polypoidal mucosa, the Ki-67 immunolabelling of
cells was mainly present in the basal layer of the epithelium.
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Hassid et al further classified nasal polyps into four groups based on clear-cut
distinct clinical behaviour patterns. The subgroups are: 1) single- polyps taken
from the lateral nasal wall and the middle turbinate; 2) massive- diffuse
polyposis involving entire nasal cavity; 3) ASA- nasal polyps from patients with
acetylsalicylic acid intolerance and asthma and 4) cystic fibrosis related
polyposis.58
They studied the proliferative activity of the polyps with the use of two
independent methods, computer assisted microscope analysis of isolated Feulgen
stained nuclei for the measurement of the percentage of cells in the S phase of the
cell cycle and the immunohistochemical evaluation of a proliferation associated
protein by means of the MIB 1 monoclonal antibody (detecting the Ki67 antigen).
They reported highest proliferative activity in cystic fibrosis related polyposis,
identifying it as being distinct from other nasal polyp groups. Overall, acute
inflammatory nasal polyps exhibited a higher cell proliferation than chronic
ones. 58
A further extension of our studies would be to review the case records of the
anonymous archival tissue. In doing so, a further stratification of the nature of
the nasal polyp (i.e. single, unilateral vs. multiple, bilateral, first presentation vs.
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recurrent) and the risk factors of the patients (i.e. presence of smoking, family
history of polyps) can be obtained. This allows analysis of data without
confounding factors as named above. However, for sub-stratification of test
samples into these groups would require much larger numbers of samples for
meaningful analysis of results. Due to the constraint of small sample size, no
further sub-stratification was undertaken in this study.
Presence of inflammatory cells and growth factors has also been proposed to
influence epithelial cell proliferation in nasal polyposis. Coste et al demonstrated
increased platelet derived growth factor (PDGF) expression in nasal polyp
epithelium, together with increased presence of macrophages (expressing CD-68
surface antigen) in the lamina propria of nasal polyps, compared with mucosa
from inferior turbinates57.
Activated macrophages are a well-known source of PDGF in various tissues,
especially in the airways. Macrophages play an important role in the
inflammatory processes mainly via an antigen-processing function and secretion
of numerous mediators such as cytokines and growth factors. The authors
further postulated that increased local PDGF secretion by numerous activated
macrophages could therefore be involved in epithelial cell proliferation up-
NASAL POLYPOSIS: MSC THESIS BY DR ANG HUI CHI, ANNETTE
117
regulation in nasal polyps. PDGF could also be involved in the pathogenesis of
nasal polyps via its connective tissue remodelling actions57.
Petruson et al demonstrated the increased presence of insulin-like growth factor
(IGF-1) in nasal polyps.90 Ohno et al. 91 reported expression of transforming
growth factor β   (TGFβ)  by eosinophils in chronically inflamed human upper
airway tissue.
TGFβ is known to have biologic activities relevant to the cellular and molecular
events in subepithelial fibrosis, such as the deposition of collagen I and III and
the increase of myofibroblasts beneath the epithelial basement membrane. They
examined the TGFβ−1  gene expression in bronchial biopsy tissue from 5 severe
asthmatics, 5 mild asthmatics and 5 normal subjects using in-situ hybridization
combined with immunohistochemical staining. 91 The density of positive cells in
severe asthmatic tissues (52.1+22.7) was significantly greater than that in mild
asthmatic tissues (1.0+1.9, p<0.01) or normal tissues (10.5+10.6, p<0.02). They
concluded that TGFβ−1 mRNA was overexpressed in severe asthmatics and that
the main source of mRNA was eosinophils, suggesting that eosinophils play an
important role in the pathogenesis of not only inflammation but also of structural
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changes, such as subepithelial fibrosis, in asthmatic airways. 91 Similarly,
eosinophils are found in large amounts within nasal polyps.1
In a related study by our research group, we investigated the composition of the
cellular inflammatory infiltrate within the nasal polyps of our Asian patients.
Immunohistochemical staining with a panel of antibodies for CD4+ and CD8+ T-
cells, B cells, Langerhan cells, eosinophils, neutrophils and mast cells was carried
out in nasal polyp tissue and middle turbinate tissue obtained from 48 patients.
The cellular infiltrate pattern in nasal polyps revealed a combined cellular
infiltrate, with significantly higher proportion of CD8+ T-cells, eosinophils and
neutrophils. An inverse median ratio of CD4+/ CD8+ T-cells was detected as,
compared with that present in middle turbinate mucosa from controls. 92  CD8+
T-cells have cytotoxic effector properties, and are important in certain viral
infections. They are a rich source of cytokines, mainly IL-2, IFNγ, TNFβ and
TNFα.91 Growth factors, elaborated by eosinophils, may result in increased
epithelial proliferation in the polypoidal mucosa as reflected by our results.
Though currently not reported, we speculate that the presence of these cytokines
may impact in the regulation of cell cycle regulator proteins, perhaps
downregulating them, such that an increased level of epithelial proliferation is
NASAL POLYPOSIS: MSC THESIS BY DR ANG HUI CHI, ANNETTE
119
attained in nasal polyps. A further extension of our study would be to correlate
the presence of inflammatory cells with the epithelial proliferation index and the
alteration of the cell cycle regulator proteins within epithelial cells.
In addition to the demonstration of a raised proliferation index in nasal polyps as
compared to non-polypoidal mucosa, there was a clear demonstrable negative
correlation between the proliferation index of the polyps and the staining indexes
of p21 and p27 cellular control proteins. These findings present an interesting
picture in the plausible explanation of the importance of the roles of the named
cell cycle proteins in the control of the mammalian epithelial cell cycle in the
pathogenesis of nasal polyps.
4.2 Cell Cycle Regulator Proteins
4.2.1 Reduced expression of suppressor protein p21
In our results, we demonstrated a significant reduction of p21 immunolabelling
of epithelial cells in nasal polyps as compared to non-polypoidal mucosa. This
reduction in p21 tumour suppressor protein suggests a decreased in restraining
of cellular proliferative activity. p21 plays an essential role in growth arrest after
DNA damage, and overexpression leads to G1 and G2 arrest or S-phase arrest.66
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Cell cycle protein p21 is a negative regulator of p53-dependent apoptosis. In
response to radiation and chemotherapy, p53 protein is stabilised and mediates
apoptosis and cell cycle arrest (See Figure 3).  Damage DNA stabilises p53
protein through yet unknown mechanisms, leading to an increase in its
concentration. 63-64
One of the genes whose transcription is stimulated by p53 encodes p21. p21
binds to and inhibits all mammalian Cdk-cyclin complexes. As a result, cells are
arrested in G1 and G2 until DNA damage is repaired and p53 and subsequently
p21 levels fall. Aging studies in p21-deficient mice have demonstrated a role for
p21 in tumour suppression, albeit a much weaker one than p53. 63-64
In a similar study published in November 2005 by Garavello et al, they studied
the expression and localization of some regulatory proteins of the cell cycle,
namely, p53, MDM2, Bcl-2, p21, p27 and cyclins A and B1 proteins. The authors
investigated the relative staining index of the named markers in the study group
consisting of polypectomy specimens (n=20), and the control group consisting of
inferior turbinate specimens (n=20). Of interest and relevance to our study, they
reported an overexpression of p53 and no variation in the expression of p21 and
p27 in nasal polyp mucosa. Within the respiratory lining epithelium of the
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specimens, they reported a p21 expression index of 2% for nasal polyps versus
no reactivity detected in the control group. The antibody clone used was 4D10
(Novocastra, Newcastle upon Tyne, UK), at dilution of 1:30. 93
The differing results between our results may be related to the clone of the
antibody used and the domain recognised by the specific clone. In addition, the
antigen retrieval technique, though not extensively detailed in the authors’
methodology, appears different from our technique. Most importantly, the
authors did not employ any statistical analysis to test the significance of their
reported results. All these factors may result in the varying conclusions of our
two studies.
4.2.2 Reduced expression of suppressor protein p27
Likewise, there is reduced expression of p27 protein in nasal polyps as compared
with non-polypoidal mucosa. p27 works very closely with p21 protein in the
eukaryotic cell cycle. p27 cell cycle protein is active in the G1 phase of cell
division.  The p27 protein bears some similarity to p21 and also inhibits several
CDKs66. Downregulation of p27 accompanies progression through G1 phase and
is permissive for the periodic activation of cyclin E-cdk 2 and cyclin A-cdk270.
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The antimitogenic role of p27 was reinforced by the p27-knockout mouse, which
is larger than its wild-type littermate. It had multiorgan hyperplasia as well as
increased susceptibility to cancer in multiple tumour models68. A low level of p27
is a marker of poor prognosis in several human adenocarcinomas.  However, no
mutations in the p27 gene have been reported to date70.
In keeping with its role as a negative regulator of cell cycle, levels of p27 are high
in quiescent cells but decreased in response to mitogens. Intracellular levels of
p27 are largely controlled by the rate of p27 degradation, which occurs through
the ubiquitination and subsequent proteasome-mediated proteolysis.
In our study, there is significant decreased expression of p27 protein in the
epithelium of the nasal polyp mucosa, as compared with that of non-polypoidal
inferior turbinate mucosa. A possible postulation is that the presence of
mitogens, alluded to in the study by Coste et al.57, resulted in a downregulation
of p27 expression, and perhaps, p21 expression too.
Keles et al.94 reported on p27 expression in nasal epithelium of inverted
papillomas and squamous cell carcinomas (SCC). They conducted their study in
16 inverted papillomas and 6 SCC of the nasal epithelium. The expression
pattern of p21, p27 and p53 were studied by immunohistochemistry. They
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reported a significant decrease in p27 nuclear staining observed in SCC of
paranasal sinus compared with inverted papillomas. Keles et al. did not find
significant differences in p21 and p53 immunolabelling in inverted papillomas
and SCC. 94 The decreased expression of p27 correlated with increased cell
proliferation in these tumours. However, our study also noted a decrease in p27
expression in nasal polyp mucosa. Nasal polyps are benign lesions which have
not been shown to progress to carcinoma.
Perhaps, it is interesting to speculate whether, in these various benign and
malignant lesions of the nasal epithelium (nasal polyps, inverted papillomas and
SCC), there is a progression of degree of dysregulation of growth and
development, which may be reflected by a progressive decrease in p27
expression with the demise of orderly proliferation and differentiation.
4.2.3 Absence of differential expression of suppressor protein p53
Ingle et al. studied the expression of p53 protein in a variety of benign epithelial
lesions of upper respiratory tract. 95 They studied a total of 109 cases of which
consisted of 16 cases of juvenile laryngeal papillomas, 36 cases of adult laryngeal
papillomas, 10 cases of laryngeal nodules, 17 cases of inverted papillomas and 20
cases of nasal polyps. The authors report the demonstration of p53 over-
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expression in 2 (10%) of 20 cases of nasal polyps. In contrast, other studies of p53
expression found no or insignificant expression of p53 protein in benign lesions.95
Watling et al. found no instances of p53 overexpression in specimens from 22
patients with benign lesions of head and neck. 96
Lavezzi et al. in 1999 investigated the biological features usually associated with
human malignancies, in an attempt to better understand the pathogenesis of
nasal polyps. 97 They elucidated the PCNA proliferative index in 32 specimens of
nasal polyps (all patients were non-smokers in preceding 3 years of the study)
and correlated this index to the intensity of staining with p53 antibody in the
lining epithelium. 75% of their cases showed positive immunoreactivity for p53
protein. In addition, in cases with intense staining of p53 protein, the PCNA
index is correspondingly higher than the mean index. The authors conclude that
p53 overexpression plays an important role in the pathogenesis of nasal polyps
and could represent the first stage which occur in the respiratory epithelium in
areas where nasal polyps form. 97
In a similar study by Garavello et. al, as discussed in the earlier section on p21
results92 (refer to page 115), the authors reported an overexpression of p53 in
polypoidal mucosa. In this study, the authors detected p53 expression in 10-20%
of the nasal polyp specimens, and no p53 expression in non-polypoidal tissue.
The results were not tested by statistical methods.
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Our results did not reveal a significant overexpression of p53 protein in nasal
polyp epithelium. A significant number of both our nasal polyp and inferior
turbinate mucosa specimens stain negatively for p53 protein. However, we were
unable to elucidate a smoking history in the patients from which our specimens
were obtained. This would have aided us in the interpretation of our results,
especially in cases (both nasal polyp mucosa and inferior turbinate mucosa)
which have stained positively for p53 protein. It is unlikely that p53
overexpression plays a role in the epithelial proliferation in nasal polyps.
We reported a mean p53 immunolabelling index for nasal polyp of 5.97 (+5.37)
2.51 (+1.00) in non-polypoidal mucosa. (See Table 3). Though our statistical tests
did not reveal any significant difference between the two groups, it may be
prudent to further increase the sample size. In the presence of larger sample size,
the trend of higher p53 expression in nasal polyp mucosa may prove to be
statistically significant.
4.2.4 Reduced expression of suppressor protein p63
Our data revealed a remarkable difference in the p63 immunolabelling in
polypoidal and non-polypoidal mucosa. In nasal polyps, p63 immunolabelling is
restricted to one- to two-cell thick layer in the basal layer of the epithelium. In
strong contrast, within the non-polypoidal mucosa, p63 immunolabelling is
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present in a two- to four-cell thick layer in the basal layer of the epithelium. This
difference is tested to be statistically significant. This finding clearly suggests a
dysregulation of not only cellular proliferation, but also, of cellular
differentiation.
The p63 gene, a homologue of the tumour-suppressor p53, is highly expressed in
the basal or progenitor layers of many epithelial tissues. p63 is highly expressed
in basal cells but is rapidly degraded upon their differentiation. It is likely that
p63 preserves the self-renewal capacity of progenitor cells that undergo
asymmetric division to yield simultaneous regenerative and differentiated cell
fates. 76
Yang et al. proposed a model of mechanism of action of p63 protein in the
regulation of cellular proliferation and differentiation (See Figure 22). Stem cells
in the basal layer of stratified squamous epithelia express high levels of p63 and
undergo asymmetric division to enable both self-renewal and progression to
transient amplifying cells (TACs). TACs, which may express less p63, are also
capable of limited proliferation and self-renewal, but are ultimately destined for
terminal differentiation. The absence of p63 results in the failure to maintain a
basal cell population, suggesting a requirement for p63 in the regenerative aspect
of stem cell division. 76
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Figure 20. Model for p63 in maintaining the proliferative capacity of
epithelial progenitor cells. 76
In non-polypoidal mucosa of the inferior turbinates, we demonstrated the
intense staining of  2 to 4 layers of cells in the suprabasal region. This observation
suggests that p63 is expressed not only in the basal stem cells, but also in
differentiating epithelial cells in non-polypoidal mucosa of inferior turbinates. In
contrast, in nasal polyp mucosa, the basal layer of darkly staining p63 cells was
only one-cell thick.
In addition, we observed that these areas were associated with squamous
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findings, it is highly likely that under-expression of p63 in diseased nasal polyp
mucosa reflects a dysregulation of differentiation, in addition to proliferation, in
basal cells of diseased epithelium. To date, there is no published data on p63
protein expression in nasal polyps and other lesions of sinonasal epithelium. This
observation however, is variant to observations made other authors whereby,
only a single layer of basal epithelial cells expresses p63 protein in the normal
state. It would be interesting to increase the sample size of non-polypoidal
mucosa to ascertain the expression profile of p63 in normal differentiating nasal
epithelium.
p63 exists as multiple isotypes of two subclasses, TA (transactivating) and
ρN. ρNp63 isotypes are thought to antagonize transcription by TAp63 and p53,
and are highly expressed in squamous cell cancers.  Using mouse keratinocytes
as a biological model of squamous epithelium, it has been shown that multiple
p63 isotypes, ρN- and TA-containing, are expressed and differentially modulated
during in vitro murine keratinocyte differentiation. 77  The role of the various
subtypes of p63 proteins are just beginning to be elucidated at this point in
medical research. The antibody we employed for our immunohistochemical
protocol detects all subtypes of the p63 proteins.
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It is likely the differences in p63 expression in polypoidal and non-polypoidal
mucosa reflects a loss of regulation of differentiation of the epithelial cells in the
polypoidal mucosa. It is clear from our results that the nasal polyp mucosa
showed marked changes in epithelial differentiation - presence of squamous
metaplasia and transitional epithelium, instead of normal respiratory epithelium.
The significance of this finding of a reduced p63 expression in nasal polyps
depends on the subtype of p63 protein that is reduced.
To further investigate the significance of this early result of reduced p63
expression in nasal polyps, further techniques (RT-PCR and Western blot
analysis) may be employed to investigate the relative proportions of the subtypes
of p63 proteins present within the proliferating nasal polyp epithelium.
Identifying the targets of p63 activity, as well as the mechanisms that modulate
its expression during epithelial differentiation, represent important challenges.
4.2.5 Cell cycle regulator proteins p21 and p27 predict proliferation index
of nasal polyps
Overall, this study demonstrated clearly the reduction in the expression of
suppressor control proteins (p21 andp27) in the polypoidal tissue as compared to
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the non-polypoidal tissue. These findings strongly suggest the decreased in
orderly cellular control of the eukaryotic cell cycle in nasal polyps. The resultant
disordered epithelial proliferation is likely a contributing factor in the
pathogenesis of nasal polyposis.
With the multiple regression model (See Section 3.4.3), we demonstrated that p21
and p27 immunolabelling indexes, when factored together, negatively influences
the proliferation index of nasal polyps. Given that the activities of p21 and p27
are closely related at the cellular level, this finding supports the suggestion that
p21 and p27 work together synergistically to influence the cell cycle dynamics.
It is interesting to further investigate the role of p21 and p27 cell cycle protein
expression in nasal polyps as a predictor of its biologic behaviour. For example,
p21 and p27 expression can be used to predict the likelihood of recurrence in
patients upon their clinical presentation. Based on such risk stratification,
management of the patients can be more effectively tailored. This certainly has
important clinical uses in the day-to-day management of patients with nasal
polyps.
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4.3 Conclusion and Future directions
The findings of a raised proliferation index (as measured by Ki-67
immunostaining) together with a decreased expression of p21, p27 and p63 cell
cycle markers clearly indicate an underlying aberration of cell cycle mechanics in
the epithelial proliferation of nasal polyps.  This reduction in the expression of
cellular control proteins of p21, p27 and p63 has resulted in a correspondingly
higher proliferation index.  In addition, we demonstrated that p21 and p27 cell
cycle protein expression, when considered together, predicts the proliferation
(Ki67) index of nasal polyps.
These findings present an interesting picture in the plausible explanation of the
importance of the roles of the named cell cycle proteins in the control of the
mammalian epithelial cell cycle in the pathogenesis of nasal polyps. There are
factors present which have downregulated the expression of these factors. In our
study, these factors are not explored. Perhaps, this poses future challenges in
research in this field.
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The field of rhinology continues to evolve with new discoveries of pathogenesis,
natural history and management paradigms of nasal polyps.  The areas discussed
as follows, are perhaps, the unexplored frontier of this field.
1. The factors that result in the downregulation of cell cycle markers
require further investigation. From previous studies by other authors,
PDGF may have a role in this downregulation. Other growth factors of
interest and often associated with polyp growth include chemokines
and cytokines.
2. There are other cell cycle markers not addressed in our current study.
The Erb-2 protein and Rb protein are important components of the cell
cycle. Due to time and supply constraints, these factors were not
studied simultaneously in this project. They too are involved in the
pathogenesis of important cancer models. Perhaps, a further
investigation into their relative expression in both nasal polyp mucosa
and non-polypoidal mucosa is called for. This will afford us a fuller
understanding of the cell cycle mechanics.
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3. The relation of other factors (such as genetic background of patients
with or without family history of nasal polyps, allergies, and smoking
history) to the downregulation of cell cycle markers is another
challenging area of investigation. In our current study, we were not
able to access the patients’ case records for further investigation of
these factors. The further elucidation of any genetic factors or
environmental insults will greatly aid in the correlation of these factors
to the proliferation index and more importantly, staining indexes of
various markers. Does the onslaught of environmental insults (e.g.
smoking, allergens) trigger a series of events resulting in the final
common pathway of reduced expression of cellular proteins so
important in holding epithelial proliferation under a tight rein? If so,
does the removal of such an insult, result in lesser disease or perhaps, a
cure?
The myriad possibilities and questions pose important challenges to further
breakthroughs in this field of rhinology. It is our hope that the findings presented
have further contributed to the body of knowledge currently available in the
understanding of the pathogenesis of nasal polyps.
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ALL PHOTOGRAPHS USED IN THIS THESIS ARE OBTAINED IN THE COURSE OF THE
AUTHOR’S CLINICAL WORK. THE RELEVANT PARTIES HAVE PERMITTED THE USE OF SUCH
MATERIAL IN TEACHING/ RESEARCH PUBLICATIONS
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APPENDICES
ALL SLIDES USED IN THIS PROJECT ARE WHOLLY PRODUCED BY THE AUTHOR AND
ACCOMPLISHED WITH FACILITIES KINDLY EXTENDED BY THE DEPARTMENT OF
PATHOLOGY, NATIONAL UNIVERSITY OF SINGAPORE
NASAL POLYPOSIS: MSC THESIS BY DR ANG HUI CHI, ANNETTE
147
6.1 Reagents and buffers
6.1.1 0.05M TRIS-buffered 0.9% saline (TBS) wash buffer
Components of TBS wash buffer (10L)
For every 10L of wash buffer,
500ml of 1M TRIS pH 7.4
300ml of 5M sodium chloride (NaCl) solution
9200ml of distilled water
6.1.2 0.001M TRIS-EDTA buffer pH 9.0 for antigen retrieval
Components of TRIS-EDTA buffer (1000ml)
For every 1000ml of TRIS-EDTA buffer,
10ml of 1M TRIS pH 8.0
2ml of 0.5M EDTA
988ml of distilled water
pH of the final solution is adjusted by the titration of sodium hydroxide solution (NaOH).
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6.2 Laboratory Protocols in Detail
6.2.1 Tissue Processing
Before any microscopic examination can be done on a piece on a piece of tissue, it has to
undergo tissue processing. Tissue processing is the treatment that allows paraffin
impregnation.
When a biopsy is taken from a patient, it must be fixed. Fixation preserves cells and
tissue constituents in a condition identical to that existing during life. It also allows
tissues to remain unchanged by subsequent treatment. Fixation should be performed
immediately since delay permits autolysis and drying. 10% neutral buffered neutral
formalin is considered the best general fixative.
After fixation, the tissues undergo dehydration, clearing and infiltration – the three
stages of tissue processing. The purpose of these sequential steps is to remove the
extractable water from tissue specimens and replace it with a medium that solidifies (e.g.
paraffin wax) to allow sectioning. Alcohols- isopropyl or ethyl- are the usual choice for
dehydration to remove the fixative and water from the tissue. Xylene is routinely used to
replace the dehydrating fluid with a fluid that is totally miscible with both the
dehydrating fluid and the embedding medium, paraffin wax.
After complete impregnation with wax, it is necessary to obtain a solid block containing
the tissue by the process of embedding. This is achieved by filling a mould of suitable
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size with molten wax, orientating the specimen in the mould to ensure it is being cut in
the right plane and cooling the mass to promote solidification.
Embedding is usually done in an embedding center. An embedding center comprises of
3 main compartments:
• Wax dispenser: automatically dispensed appropriate amount of wax into
cassette.
• Cold plate: allow the wax at the base of the mould to semi-congeal for easy
orientation of tissue and also to cool the paraffin wax quickly.
• Heated storage area for moulds: to maintain wax in liquid state so that bacteria
do not grow.
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6.2.2 Tissue Processing Schedule
Automatic tissue processors enhance the processing of tissues by using heat, vacuum,
pressure and agitation.
Table 8. Tissue processing schedule
Bath Reagent Routine ProcessingSchedule
Short Schedule for
Biopsies
1 10% Formalin 2 Hr 30 min
2 70% Alcohol 1 Hr 15 min
3 95% Alcohol I 1 Hr 15 min
4 95% Alcohol II 1 Hr 15 min
5 Absolute Alcohol I 1 Hr 15 min
6 Absolute Alcohol II 1 Hr 15 min
7 Absolute Alcohol III 1 Hr 15 min
8 Xylene I 1 Hr 15 min
9 Xylene II 1 Hr 15 min
10 Xylene III 1 Hr 15 min
11 Paraffin I 2 Hrs 45 min
12 Paraffin II 2 Hrs 45 min
Total: 15 Hrs 4 Hrs 15 min
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6.2.3 Paraffin Embedding Protocol
1. Transfer the cassettes containing the dehydrated and infiltrated tissues from the
tissue processor into the cassette bath.
2. Open a processing cassette in order to view the tissue sample and orientate the tissue
as desired.
Note: Discard the lid of the embedding cassette.
3. Select a mould that best corresponds to the size of tissue and place it under the
dispenser outlet nozzle.
4. Partly fill the mould with paraffin and transfer to the refrigeration unit.
5. With a warm forceps, transfer the previously orientated tissue, place it at the bottom
of the mould and press gently to hold the tissue in place.
Note: The above must be carried out rapidly to avoid a film to form on the surface of the
paraffin. Otherwise, this would create two phases in the finished block leading to
fissures, which subsequently may cause the block to break during sectioning.
6. Place the cassette base above the mould and fill to brim with paraffin.
7. Transfer the mould carefully to the cold plate. The paraffin should solidify in about
15-30 minutes, after which the paraffin block can be easily removed from the mould
and is now ready for sectioning.
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6.2.4 Microtomy
Tissue can be sectioned, attached to a surface and examined under a microscope.
Microtomy involves the following:
6.2.4.1 Trimming
Before sectioning a block, examine it and establish how it should be oriented in the block
holder. Set the thickness setting to about 15μm and trim the block till the entire surface of
tissue is exposed. The tissue block is then placed on cooler or into ice water for soaking,
allowing for better, flatter and thinner sections.
6.2.4.2 Sectioning
Set the thickness setting to about 3-5 μm. The hand wheel should be turned at a slow and
even speed to produce a long ribbon of sections of even thickness. Interrupted motion or
change of speed results in uneven thickness of the sections.
6.2.4.3 Flotation
A camel’s hair brush, a fine-eyed forceps or a dissecting needle may be used to
handle the ribbon as it comes out of the microtome knife. Float the ribbon into a bath
of 20% alcohol prior to floating it on the warm water bath, which is set at about 47 ºC
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to 51ºC. The ribbon is then gradually lowered onto the water bath to eliminate
wrinkles and entrapped air. Allow the sections to remain on the water bath until
they are flattened. The sections are separated and placed onto cleaned pre-labelled
polylysine slides.
6.2.4.4 Draining and Drying of Slides
The slides are then drained vertically, failure of which may result in the presence of
bubbles under the tissue and the subsequent decrease in tissue adhesion to the
slides. Air bubbles also produce section unevenness and staining artefacts. After
draining, the slides could either be placed on a warming table or oven that is set at
37ºC to 40ºC where they are to remain overnight. (Note: For immunohistochemistry
procedures, drying will have to be overnight at 37ºC to prevent destroying antigens).
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6.2.5 Hematoxylin and Eosin (H&E)
Hematoxylin is the most widely used natural dye in histotechnology and is commonly
employed as a nuclear dye in the standard H&E, the primary staining method or tissue
section analysis.
Hematoxylin is extracted from the heartwood of a South American tree Haematoxylin
campechianum. Hematoxylin itself is not a dye, rather the oxidized product of
hematoxylin – the haematein is considered the dye. Haematin is an anionic compound; it
will not directly stain tissues but needs a mordant provided by metal cation such as iron
or aluminium. Hematoxylin, being a basic dye, has an affinity for the nucleic acids of the
cell nucleus.
Hematoxylin stains are either “regressive” or “progressive”. With a regressive stain, all
tissue structures are stained and thus require a controlled decolourisation and “bluing”
steps to arrive at the optimum nuclear staining results. A progressive procedure stains
the nuclei only. An example would be the Gills’ III hematoxylin which is used in the
author’s laboratory.
Eosin is an acidic dye with an affinity for cytoplasmic components of the cell. Proteins
are generally cationic below pH 6 and will thus bind to eosin. The most frequently used
form is eosin Y that gives yellowish-pink shades and be prepared as either an alcoholic
or aqueous solution.
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6.2.5.1 Procedure for Hematoxylin & Eosin (H&E) Staining
1. De-paraffinize slides in 3 changes of xylene
2. Hydrate the slides through the series of graded alcohols (absolute to 95% to 70%
alcohols) before bringing the slides to water.
3. Stain the slides in freshly filtered Gills’ III Hematoxylin for 2-5 minutes, depending
on the intensity desired.
Note: Gills’ III Hematoxylin is a progressive hematoxylin stain, which only stains the
nucleus. Thus, controlled decolourisation in acid alcohol not required unlike in the
regressive hematoxylin stain procedures.
4. Wash in running tap water briefly.
5. Give the slides a single dip in the ammonium hydroxide bath until sections turn
“blue”.
6. Wash briefly in tap water.
7. Stain the slides in eosin for 1-2 minutes.
8. Dehydrate the slides through the series of graded alcohols (70% to 95% to absolute
alcohols).
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Note: Leave the slides longer in the absolute alcohols baths to completely dehydrate the
slides since any presence of water droplets may result in the presence of water droplets
on the sections even after mounting.
9. Clear the sections in 3 changes of xylene.
10. Mount the sections in DPX.
RESULTS
Nuclei ……………………………………………….. Blue
Cytoplasm …………………………………………… Pink to Red
Most other tissue structures ………………………….. Pink to red
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6.3 Data
Staining proportions of the individual slides are presented here. The figures shown are
the averages of readings of 2 independent observers (each of 3 random fields).
Table 9. Ki-67 immunolabelling
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Table 10. p21 immunolabelling
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Table 11. p27 immunolabelling
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Table 12. p53 immunolabelling


























NASAL POLYPOSIS: MSC THESIS BY DR ANG HUI CHI, ANNETTE
162
Table 13. p63 immunolabelling
Serial No Nasal polyp Inferior turbinate
1 35.39 60.22
2 33.88 75.83
3 46.47 56.25
4 28.93 45.74
5 65.25 47.87
6 26.6 49.04
7 28.6 57.14
8 27.66 88.14
9 32.81 61.22
10 37.5 52.72
11 34.18 -
12 44.68 -
13 30 -
14 22.46 -
15 9.8 -
16 30.11 -
17 31.62 -
18 25.53 -
19 41.41 -
20 42.98 -
21 32.65 -
22 42.9 -
23 23.11 -
24 61.54 -
25 12.56 -
